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1. INTRODUCTION AND JUSTIFICATION 
Peripheral Vascular disease refers to the disorders affecting the vessels that are not 
directly in relation to the heart (1). The most commonly seen conditions are lower 
limb venous insufficiency and peripheral arterial disease. The prevalence and risk 
factors of these diseases have not been studied extensively at the community level in 
India. 
Atherosclerosis is a systemic disease affecting the medium and large arteries. The 
pathophysiology of this disease involves the accumulation of fibrins and lipids 
between the tunica intima and media of the vessels leading to narrowing of the vessel 
lumen. This, in turn, causes decreased blood flow which may lead to ischaemia. If this 
occurs in a non-cardiac or cerebral vessel, it is called peripheral arterial disease. It is 
commonly diagnosed by measuring ankle brachial pressure index (ABI). An ABI of 
less than 0.90 is considered diagnostic of peripheral arterial disease (2). An ABI of 
more than 1.30 is suggestive of non-compressible vessels and is also indicative of 
arterial disease (3), especially of the systemic kind.  
A U-shaped curve is seen while predicting all cause mortality and cardiovascular 
mortality as far as the ABI is concerned. Both low (adjusted OR 1.69, 95% CI 1.34-
2.14) and high (adjusted OR 1.77, 95%CI 1.48-2.13) values predicted mortality (4). 
 
There are various reasons for decreased peripheral blood flow, like inflammation, 
thrombosis and most commonly atherosclerosis.  Most of the peripheral arterial 
disease patients are asymptomatic until the time they develop gangrene leading to loss 
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of limb. According to Sabiston’s Textbook of Surgery, 20% - 50% Peripheral Arterial 
Disease (PAD) cases are asymptomatic. Only 10% – 35% present with claudication 
pain and another 20% present with nonspecific local symptoms. Diagnosis of PAD is 
critical because people with PAD have 4-5 times the risk of a heart attack or a stroke 
than the age-matched population (5). These asymptomatic patients realize their 
predicament too late, even for secondary prevention. They continue to smoke and are 
non-compliant with medications for diabetes mellitus as they are asymptomatic and 
lead a comfortable life, therefore not needing to change their current lifestyle. It is a 
known fact and proven by studies that prevalence of PAD is associated with diabetes 
(6), male gender, smoking, hypertension, dyslipidaemia, race, hyperhomocysteinemia 
and renal disease (5). According to a study done in urban Chennai, the prevalence of 
PAD in the general urban population was 3.2%. It found that age and hypertension 
were the major risk factors. The prevalence was 7.8% among those with known 
diabetes (6). In a cross-sectional study done in the United States of America over a 
period of five years between 2003 and 2008 among 3.6 million participants, the 
prevalence of PAD was 3.6% in the general population with an exponential increase in 
successive decades of life (7). 
A study done in Japan comparing a cohort of 362 patients with PAD and a matched 
cohort without PAD revealed a higher risk of myocardial infarction (2.2% against 
0.2%, p-value 0.019), ischaemic stroke (4.1% vs 0.5%, p-value 0.001) in the first year 
of the study. Total annual health costs were significantly higher in the PAD cohort (p-
value <0.001)(8). In the United States, a total of $4.37 billion was spent by the 
national health insurance program (Medicare) on peripheral arterial disease-related 
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medical care in 2001, 88% of which was spent on inpatient care. The expenditure 
increased with age of the patient as they needed longer inpatient treatment (9).  Over 
the past 17 years, the cost is bound to have dramatically risen. Early identification is a 
must in these circumstances.   
In a study done in the US and five major European countries (France, Germany, 
Spain, Italy and the United Kingdom) increased absenteeism, overall work impairment 
and difficulty in activities of daily living were seen in people with PAD (p<0.05). 
Similarly, the number of outpatient visits, inpatient treatment and casualty visits were 
higher in the PAD group (p<0.05) (10). Another study estimated a cumulative cost of 
$7,445 for asymptomatic PAD patients, $7,000 for patients with claudication, $10,430 
in patients with lower limb amputations secondary to PAD and $11,693 in patients 
who had revascularization over a period of two years (11). In France, a cohort study 
done from 2007-2011 evaluated that the total annual management cost in the PAD 
group was €14,949 as opposed to €3812 in the control group (12). 
PAD can affect the mental well-being of those affected. A systematic review of 28 
studies found the prevalence of depression among those with PAD to be as high as 
36% to 48%. The study also found that women with PAD were more pre-disposed to 
have depression (13). Depressive symptoms among patients with PAD above the age 
of 65 was estimated to be 30% - 60% (14). 
Low ABI can be used as a surrogate for predicting cognitive decline and may be used 
to identify people who could potentially end up with cognitive impairment (15). It has 
been said that 8% - 67% of patients with PAD perform poorly (<5% of controls) when 
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tested on non-verbal memory, concentration, executive function, perceptuo-motor 
speed and manual dexterity (16). 
Peripheral venous insufficiency is a chronic condition, most commonly associated 
with incompetent valves. It encompasses a vast array of morphological and functional 
abnormalities over a prolonged period of time (17). In standing position, if the 
subcutaneous veins in the lower limbs are measured at more than 3 mm in diameter, 
then it is defined as a varicose vein (18). According to certain studies done in India 
and the United States (extrapolation), the prevalence of venous disease is 15-20% in 
India (17,18). Female gender, hereditary predisposition, trauma, occupation and 
pregnancy were found to be major risk factors (20). Congenital varicose veins are also 
seen in some individuals (17). Peripheral vascular disease, especially venous 
congestion, is a preventable cause of chronic ulcers/gangrene/ Deep Vein Thrombosis 
(DVT)/amputation if diagnosed at an early stage and treated appropriately. A 
spectrum of venous abnormalities including intradermal venous dilatation, 1-3 mm 
size venules as well as varicose veins falls under chronic venous disorder (17). 
Chronic venous disorders lead to chronic venous insufficiency which causes tissue 
damage due to perivascular inflammation. Due to various cytokine-mediated 
mechanisms, the dermal barrier is weakened and is easily infiltrated by pathogens and 
allergens (21).  
The Bonn Vein Study done in Germany among 3072 patients showed that  49.1% of 
the men and 62.1% of the women between the ages of 18 and 79 had symptoms of 
chronic venous disease (22). The American Venous Forum conducted a National 
Venous Screening Program among 2234 individuals.  The prevalence of venous 
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disease based on the CEAP classification from C0-C6 was 29%, 29%, 23%, 10%, 9%, 
1.5% and 0.5% respectively (23). It is very common for less severe forms to progress 
to chronic venous congestion.  70% of people with advanced Chronic Venous Disease 
had had previous venous disorder as opposed to only 30% who had the disease after a 
thrombotic incident (24). 
 In the United States of America, it has been estimated that the annual expenditure 
(direct medical cost) on Chronic Venous Disease may be anywhere between 150 
million and 1 billion US dollars (25).  In the United Kingdom, 2% of the health care 
budget is spent on venous ulcers. GBP 5.7 billion is spent per year for managing all 
types of wounds.19% of these wounds were leg ulcers. According to this study, 1.5% 
of all adult population had an undifferentiated leg ulcer. There were 278,000 venous 
ulcers noted in that year which indicates that 1 in 170 adults had an ulcer in the study 
year ( 25).   
It is commonplace to underdiagnose and subsequently not treat people with venous 
disease. This leads to the development of complications and the attending financial 
and social burden on the patient and the society. Chronic venous ulcers are recurring 
and it also is associated with discharge, foul smell, ghastly appearance and these have 
physical, psychological and emotional implications. A systemic review shows that 
chronic venous disease negatively affects the quality of life among individuals (27). 
Pain, fatigue and lack of mobility have been found to be some of the physical impacts. 
Lack of mobility in itself further leads to worsening of the venous congestion and ends 
up as a vicious cycle.  Social isolation, altered body image, lack of sleep, frustration 
have all been associated with venous leg ulcers. Fear of isolation and dependence is 
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another key issue faced by patients with chronic venous congestion (28). Lower 
education and low income were further found to complicate quality of life among 
people with chronic venous disease. Younger people with the disease were found to 
have more psychosocial burden (29). A study done in Sao Paulo among 60 people, 
estimated prevalence of depression among patients with venous disease to be 91.66%. 
Sadness, negative body image, feeling of worthlessness, decreased libido and social 
withdrawal were the five main symptoms commonly associated with chronic venous 
disease. One person in the study even reported suicidal ideation (30). 
As there is a paucity of information on peripheral arterial and venous disease 
particularly in the rural Indian community, this study was carried out to determine the 
prevalence and risk factors for peripheral vascular disease in such a population. 
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2. OBJECTIVES 
• To estimate the prevalence of Peripheral Arterial Disease (PAD) among adults 
in a rural community in South India. 
 
• To estimate the prevalence of Chronic Venous Disease (CVD) among adults in 
a rural community in South India. 
 
 
• To assess the associated risk factors of Peripheral Arterial Disease among 
adults in this population 
 
• To assess the associated risk factors of Chronic Venous Disease among adults 
in this population. 
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3. REVIEW OF LITERATURE 
1. Peripheral Arterial Disease (PAD) 
 
Peripheral arterial disease is the term used for partial or complete obstruction of one or 
more peripheral arteries (upper and lower limb extremities) (31). Globally 202 million 
individuals were living with peripheral arterial disease, out of whom 69.7% patients 
were from Low and Middle-income countries. 54.8 million individuals were from 
Southeast Asia alone (32). The prevalence of PAD by age as described by the Trans-
Atlantic Inter-Society Consensus document is given below (33). 
Fig 3.1 Prevalence of PAD by age group 
(34) 
Source: Journal of Vascular Surgery Volume 45, Issue 1, Supplement, January 2007, 
Pages S5-S67 
1.1 Definitions and Nomenclature for vascular diseases as defined by the 
Atherosclerotic Peripheral Vascular Disease Symposium II published in 2008 (31) :  
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Asymptomatic PAD: Abnormal ABI at rest or after exercise, or other objective 
evidence of PAD but no limb symptoms. (31) 
Claudication: Abnormal ABI at rest or after exercise with reproducible lower 
extremity muscle fatigue or discomfort on exertion, relieved by rest within 10 mins  
(31). 
Atypical Claudication: Abnormal ABI at rest or after exercise with leg pain on 
exertion that is not consistent with classic claudication; may include calf, thigh, or 
buttock (31). 
Critical Limb Ischaemia: Haemodynamic evidence of severe PAD with distal leg pain 
at rest, with or without ischaemic ulcers or gangrene (31). 
Acute Limb Ischaemia: Haemodynamic evidence of severe PAD with acute limb pain 
and neurological dysfunction (31). 
Abnormal ABI refers to an ABI <0.90 or >1.30 as both are associated with an 
increased prevalence of PAD both locally and systemically (35). 
1.2 Anatomic localization of types of presentation 
Asymptomatic: The Progression of Early Subclinical Atherosclerosis (PESA) study in 
4184 asymptomatic participants between the ages of 40 and 54 showed subclinical 
atherosclerosis in 63% of the population (71% among men and 48% among women) 
(36).  The obstructive plaques were most commonly seen in the iliofemoral region 
(44%), followed by the carotid arteries (31%) and the aorta (25%). The coronaries had 
plaques in only 18% of the people. In another study, 72% of men aged between 40 and 
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59 had asymptomatic atherosclerosis (37). Magnetic resonance angiography is 
however not necessary or indicated in asymptomatic patients.  
Symptomatic: A series of 11.890 patients with atherosclerosis who were symptomatic 
were followed up for 25 years and were found to have the disease in four major 
arterial beds. These are, the coronary arterial bed, the major branches of the aortic 
arch, the visceral branches of the abdominal aorta and the terminal abdominal aorta 
and its major peripheral branches. In this study, it was found that prevalence was 
highest in the lower extremity arteries followed by the coronary arteries. It also 
showed that patients with coronary artery atherosclerosis and visceral artery disease 
presented much earlier and at a younger age group than patients with peripheral 
arterial disease. The rate of progression of the disease also differed substantially. It 
was fastest in the aortic arch and the visceral bed. Patients with concomitant risk 
factors like smoking and co-morbid illnesses like diabetes mellitus had the greatest 
risk for progression of the disease.  Interestingly, a disease in the abdominal aorta and 
its terminal branches had the highest probability of developing the disease in a new 
arterial bed while the coronary disease patients rarely developed atherosclerosis in any 
further regions. Disease in the aortic branch was most likely to progress to disease in 
the abdominal aorta and its terminal branches and vice versa (38). It has been found 
that diabetes is more common among people with distal atherosclerosis (p=0.004) 
than in those with proximal arterial disease (39). 
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Risk Factors of PAD 
44,985 men in the United States of America with no cardiovascular disease at baseline 
were part of the Health Professionals Follow-up Study and were followed up for a 
median of 24.2 years. There were 537 incident cases of PAD. After adjusting for each 
other factor, it was found that Type 2 Diabetes, smoking, hypercholesterolemia and 
hypertension were all significantly and independently associated with an increased 
risk of PAD. Men without any of the four risk factors were found to have a hazard 
ratio of 0.23 (95% CI 0.14-0.36) which signifies a 77% protection. Each additional 
risk factor had a multivariable-adjusted hazard ratio of 2.06 (95% CI 1.88-2.26) (40). 
A systemic review of community-based studies showed that prevalence was less 
among men in Low or Middle-Income Countries (LMIC) as opposed to High-Income 
Countries (HIC), 2.89% vs 5.41% in the 45-49 year age group and 14.94% vs 18.83% 
in the 85-89 year age group. In LMIC, prevalence was higher among women than men 
especially in the lower age group (6.31% vs 2.89%). Smoking was found to be a major 
risk factor in both LMIC and HIC (OR 1.42, 95% CI 1.25-1.62 and OR 2.72, 95% CI 
2.39-3.09 respectively). Other risk factors in LMIC and HIC respectively are, Type 2 
Diabetes Mellitus (1.47[1.29-1.68] vs 1.88[1.66-2.14]), hypertension (1.36[1.24-1.50] 
vs 1.55[1.42-1.71]) and hypercholesterolemia (1.14[1.03-1.25] vs 1.19[1.07 vs 1.33]) 
(32). 
The National Health and Nutrition Examination Survey (NHANES) done in the 
United States of America in 1999-2000 showed that Black Americans (OR 2.83), 
hypertensives (OR 1.75), diabetics (2.71), patients with dyslipidaemia (OR 1.68), 
people with poor renal function (OR 2.00) and above all, current smokers (OR 4.46) 
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were at a higher risk of developing Peripheral Arterial Disease. Elevated blood 
fibrinogen levels and C-reactive protein were also found to be associated with PAD 
(41).  
Among a random sample of patients from the prospective cohort ‘Men born in 
1914’in Malmo, Sweden, it was found that the median plasma triglyceride levels and 
mean systolic blood pressure were higher in patients with ABI less than 0.90 (42). In 
the same cohort, the prevalence of PAD was found to be significantly higher among 
diabetics than non-diabetics (29% vs 12%, p=0.003) and also associated with 
increased cardiac events and a higher incidence of cardiac mortality among diabetics 
with PAD (43).  
Data from the Atherosclerosis Risk in Community (ARIC) study showed that 
increased Low-Density Lipoproteins (LDL) and decreased High-Density Lipoproteins 
(HDL) were seen in people with lower ABI (<0.90). It was also found that ABI of 
<0.80 or >1.20 had a higher proportion of men and the mean height was significantly 
more (p<0.001) (44).  
In a study done among 114 French Canadians who had had an angiography and been 
confirmed to have peripheral vascular atherosclerosis, it was found that high plasma 
triglyceride concentration was associated with increased severity of atherosclerosis, 
especially in the younger age group. On paper electrophoresis, 56.1% of patients with 
PAD had normal lipoprotein pattern (45). The original cohort of the Framingham 
heart study was followed up for 38 years and risk profile for intermittent claudication 
was identified. Cigarette smoking, coronary artery disease, diabetes, hypertension, 
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increased serum cholesterol, age and male sex were found to be associated with an 
increased risk of PAD (46). Relative risk was highest for cigarette smoking followed 
by diabetes, hyperhomocysteinaemia, hypertension and hypercholesterolemia (47). 
A nested case-control study was done using blood samples which were collected 
initially from a concurrent cohort of 14,916 male physicians aged between 40 and 84 
years in the United States, who were healthy at baseline. With a mean follow up of 9 
years 140 men developed PAD. It was found that higher levels of CRP, fibrinogen, 
Apolipoprotein B-100, Total Cholesterol, Triglycerides, LDL and total cholesterol-
HDL ratio and lower levels of HDL, Apolipoprotein A1at baseline were good 
predictors of developing PAD. High Total Cholesterol-HDL was found to be the 
strongest predictor (RR 3.9, CI 1.7-8.6) after multivariate analysis. CRP was also a 
strong predictor (RR 2.8, CI 1.3-5.9) according to the study (48). The extent of lower 
limb disease in young patients was found to be strongly associated with post-
methionine plasma homocysteine level (p=0.003) (49). Another meta-analysis 
revealed a significant association between hyperhomocysteinemia and PAD (OR 6.8, 
CI 2.9-15.8) (50).  
The Framingham cohort revealed that abdominal aortic calcification had a moderate 
positive linear relationship with hereditary factors (R=0.49, p<0.001) (51).  Another 
study looked at the intimal-medial thickness of the common carotid artery and internal 
carotid artery and its heritability and found that the coefficient of correlation was high 
in both cases (R= 0.92 and 0.86 respectively) (52). A study done among Latin 
American families found that genetic factors were responsible for 50% of the 
variability of intima-media thickness of arteries (53). 
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Age: Increasing age has been found as an unequivocal risk factor for PAD. The 
NHANES study (41) has shown the following prevalence of PAD in each age group, 
-above 80 years of age:  23.2% 
-above 70 years of age:  14.5% 
-from 60 to 69 years of age: 4.7% 
-from 50 to 59 years of age: 2.5% 
-from 40 to 49 years of age: 0.9% 
Sex: Though literature is ambiguous about predominance in either sex, most of the 
available studies show a predilection in men. The comparison of global estimates of 
prevalence of peripheral artery disease shows no significant difference in prevalence 
between men and women (32).  
The German Epidemiological Trial on Ankle Brachial Index (getABI) was done 
among 6880 consecutive primary care patients above the age of 65 years. It showed a 
prevalence of PAD as 19.8% among men as opposed to 16.8% among women (54). 
Cigarette smoking: Cigarette smoking has also been shown as a significant risk 
factor for PAD. It is a predisposing factor of atherosclerosis by causing vascular 
endothelial damage, releasing free radicals and thrombosis (55). Nicotine and cotinine 
were found to cause smooth muscle cell proliferation resulting in intimal 
hyperplasia(56). It causes endothelial dysfunction, increases platelet adhesion and 
aggregation and also influences the formation of the fibrin framework thereby 
activating the coagulation cascade and promoting thrombus formation (57). This 
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process was found to be augmented in younger women who were on oral 
contraceptive pills. Cigarette smoking has also been found to increase total 
cholesterol, triglycerides and low-density lipoproteins and also decrease high-density 
lipoproteins which by themselves can increase the risk of atherosclerosis (58). 
Cigarette smoking was also found to influence the sympathetic outflow thereby 
causing increased blood pressure (59). 
Diabetes Mellitus: Diabetes Mellitus is an established risk factor for atherosclerosis. 
A retrospective study of arteriograms revealed that diabetic patients had the more 
severe arterial disease in the lower limbs and also more likely to end up with an 
amputation (OR 5.4, p<0.0001) (60). A 10-year follow-up study showed that patients 
with type 2 diabetes who had an ABI < 0.90 were found to be at a higher risk of all-
cause mortality (p<0.05) and also of cardiovascular disease (HR 2.32, 95% CI: 1.27-
4.22) (61). A longitudinal cohort study done amongst residents in Minnesota aged 50-
70 showed a higher risk of mortality (HR 2.9, 95% CI 1.3-4.0) among patients with 
both PAD and Diabetes (62).  
A meta-analysis of 13 observational studies was done to find an association between 
HbA1C and cardiovascular disease. It revealed a 10% to 26% increased risk of 
cardiovascular disease for every 1% increase in glycosylated haemoglobin among 
Type 2 diabetics (63).  
A retrospective study done amongst patients with atherosclerosis in the aorta and other 
peripheral arteries showed that diabetics had a 5 times higher risk of having an 
amputation and 10 times the risk of mortality in comparison to non-diabetics (64). 
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Chronic alcohol consumption (>20 years), though protective of atherosclerosis, was 
found to be a risk factor for PAD among patients with diabetes (OR 3.48, 95% CI 
1.09-11.15) (65).  
Hypertension: Hypertension is a very strong risk factor for PAD. Prevalence of 
hypertension in India was found to be 29.8% in a meta-analysis (66). This is in 
contrast to a prevalence of hypertension of 62.9% among patients with PAD in a study 
done in Kerala, India (67). The risk of developing intermittent claudication was found 
to be 2.5-4 times among hypertensives than non-hypertensive patients in the 
Framingham cohort (68). The NHANES study showed a higher prevalence of PAD 
among hypertensive patients (OR 1.75, 95% CI 0.97-3.13) (41). Prevalence of 
treatment for hypertension was also found to be lower among patients with PAD than 
in patients with Coronary Artery Disease (CAD) (69% vs 84%, p<0.001) (69).  
In the United States of America, among people older than 60 years of age, PAD was 
found to be significantly associated with untreated hypertension (OR 1.68, 95%CI 
1.13-2.50) as well as uncontrolled hypertension (OR 1.95, 95% CI 1.40-2.72) (70). 
Health records of 1.25 million people above the age of 30 years were procured from 
the CALIBER (Cardiovascular research using Linked Bespoke studies and Electronic 
health Records) programme to analyse the effect of hypertension on 12 diverse 
presentations of cardiovascular disease including PAD.  
This study found that PAD was associated more with raised systolic blood pressures 
than diastolic blood pressure readings. It also revealed an inverse relation with Mean 
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Arterial Pressure (MAP) (HR 0.90, 95% CI 0.86-0.94) and a strong association with 
pulse pressure (HR 1.23, 95% CI 1.20-1.27) (71).  
A non-concurrent cohort study which reviewed a database of over 4.2 million people 
between 30 and 90 years of age from 1990-2013 in the United Kingdom revealed a 
63% increase in the risk of PAD for a 20mmHg increase in systolic blood pressure 
(HR 1.63, 95% CI 1.59-1.66) (72). 
Dyslipidaemia: Lipids and lipoprotein abnormalities are an established cause of 
cardiovascular disease and are known to be associated with long-term adverse events. 
A case-control study showed that the prevalence of hyper-triglyceridaemia among 
men with PAD was higher by 42% compared to age and sex-matched controls (p-
value <0.05). In the same study, it was found that prevalence of hypercholesterolemia 
and hyper-triglyceridaemia was higher among women with PAD as opposed to age 
and sex-matched controls (19% more, p value<0.01 and 82% more, p value<0.05 
respectively) (73). On the other hand, High-Density Lipoproteins (HDL) and 
apolipoproteins A-I and A-II were found to be lower in patients with PAD (74). 
A cohort of men aged between 35 and 64 years was followed up from 1974 to 1990 
and the study revealed that lipoprotein-a levels were higher in men who developed 
intermittent claudication than others (46+/- 45 vs 33+/-35 mg/dL, p<0.05) (75). 
A study done on 55 Caucasian men with premature PAD (onset of disease before 45 
years of age) showed that increased lipoprotein a levels (>30 mg/dL) was a significant 
risk factor (OR 3.9, 95% CI 1.1-13.7). Raised apolipoprotein-B levels (>95 mg/dL) 
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was also found to be an independent risk factor for premature PAD among Caucasian 
men (OR 3.2, 95% CI 1.0-10.0) (76).  
In the Framingham study, it was found that the odds of developing symptomatic PAD 
went up by 1.2 for every 40 mg/dL increase in total cholesterol (46). As discussed 
earlier total cholesterol by HDL ratio was found to be a strong predictor of risk of 
PAD (48). 
Groups at risk for disease: 
The ACC/AHA (American College of Cardiology/American Heart Association) 
guidelines have listed out specific population groups at risk for Peripheral Arterial 
Disease in the lower extremities (77). These groups are: 
*People <50 years of age with diabetes and one other risk factor for atherosclerosis 
(hypertension, dyslipidaemia, current smoking etc.). 
*People aged 50-69 years with a history of smoking OR diabetes. 
*Any person who is 70 years old or above. 
*Anyone with a history of symptoms suggestive of intermittent claudication or 
ischaemic rest pain. 
*People with abnormal lower limb pulse examination. 
*Patients with coronary artery disease or known atherosclerosis in any other vascular 
site (carotid artery, renal artery). 
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Clinical Presentation of PAD 
The distribution of symptomatology among patients with PAD above 50 years of age 
is as follows (78), 
- Threatened limb/Critical Limb Ischaemia (1%-2%) 
- Classic Claudication (10%-35%) 
- Atypical leg pain (40%-50%) 
- Asymptomatic (20%-50%) 
Fontaine classified PAD based on the clinical presentation of the patients. The 
following table is the Fontaine’s classification of peripheral arterial disease (79). 
Table 3.1 Fontaine’s Classification of PAD 
Stage Symptoms 
I Asymptomatic 
II Intermittent Claudication 
II a Classic claudication on walking>200 m 
II b Classic claudication on walking<200 m 
III Ischaemic Rest pain 
IV Necrosis or Gangrene 
 
Asymptomatic PAD: A vast majority of patients with PAD are asymptomatic. They 
may be picked up while screening, by ABI or Toe Pressure Index. Identifying 
asymptomatic PAD patients is essential as it is a vital indicator of systemic vascular 
atherosclerosis. Therefore, these people are at an increased risk of cardiovascular or 
cerebrovascular events. Asymptomatic patients can be started on conservative and 
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even medical management to prevent and control risk factors. Diet, exercise, smoking 
cessation, drugs like aspirin may all be started to reduce the risk of a major vascular 
event (78).  
Atypical leg pain and Intermittent Claudication: As previously defined, 
claudication is a reproducible discomfort or pain in a particular group of muscle which 
is induced by exercise and relieved on resting. This is because of the insufficiency of 
blood supply to the concerned muscle during contraction. The blood supply may be 
adequate while the muscle group is at rest.  Claudication and atypical lower limb pain 
are the most common symptoms associated with peripheral arterial diseases.  
Patients with PAD who had intermittent claudication were found to have a higher 
prevalence of neuropathy, diabetes and spinal stenosis than controls. Similarly, people 
with atypical leg pain had fewer symptoms and their activities of daily living were 
lesser affected than patients with intermittent claudication (80). 
In the PARTNERS program, 6417 people who were ‘at risk’ of PAD were studied. It 
was found that among people who already knew that they had PAD, 25% had no 
history of leg symptoms, 61% had atypical leg pain and 14% had intermittent 
claudication. Among those who were newly diagnosed to have PAD, 47% were 
asymptomatic, 47% had atypical leg symptoms and 6% had claudication (81). 
Critical Limb Ischaemia: 1%-2% of patients with PAD above the age of 50 years 
present with threatened limb (82). Decreased perfusion, severe or extensive ulcers, 
presence and seriousness of infection can all be reasons for the threat to limb. Patients 
who present within 2 weeks of decreased limb perfusion are said to suffer from acute 
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limb ischaemia. If they present more than 2 weeks later then it becomes chronic 
ischaemia (33). 
Acute limb ischaemia is most commonly due to thromboembolism secondary to atrial 
fibrillation or similar illnesses. It can also be due to a sudden occlusion of a 
chronically narrowed arterial lumen or due to dissection of the artery. By-pass or stent 
thrombosis may also be a common cause of acute limb ischaemia in people who have 
previously undergone intervention for PAD (78). 
Chronic limb ischaemia is usually due to multiple occlusions in various segments of 
the arterial tree. However, isolated tibial artery disease has been known to cause 
chronic ischaemia in patients with diabetes mellitus especially among the elderly. 
Aortoiliac, femoropopliteal, and tibial segments are most frequently affected by 
atherosclerosis (83). Atherosclerotic plaques at various levels affect collateral 
circulation as well as decreasing the distal systolic blood pressure thereby affecting 
distal tissue perfusion. Chronic ischaemia may present with rest pain, gangrene or 
ulceration. 
Symptomatology 
Lower Limb Pain – This is the most common presentation of PAD. Patients may have 
different types and severity of pain depending on the extent of ischaemia. Most 
commonly, patients present with complaints of pain during activity which is relieved 
on rest especially over the buttocks, thigh and calf. This is repeatable and is called 
intermittent claudication. Patients may also present with rest pain, wherein they have a 
constant foot pain which increases on elevating the foot and is relieved by 
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dependency. Atypical lower limb pain is also a common but non-specific symptom of 
PAD (78). 
Claudication - Claudication is a term derived from the Latin word for limp. Classically 
Claudication presents as pain in the lower limbs after walking for a certain period of 
time and is relieved in less than 10 minutes of rest (31).  
Isolated claudication of the foot is an uncommon presentation in PAD. It occurs in 
tibial or peroneal vessel occlusive disease. Calf pain, on the other hand, is the most 
common presenting complaint in PAD. It is usually due to femoropopliteal occlusive 
disease. Aortoiliac disease and common femoral artery atherosclerosis may cause 
buttock/hip or thigh claudication and also impotence in men (84). 
Atypical limb discomfort - Atypical leg symptoms may be more common than 
claudication among patients with PAD as the perception of pain may vary due to co-
morbid illnesses and physical inactivity. Atypical limb complaints may be due to 
various other causes like neuralgia, myalgia, arthritis etc. All other causes must be 
considered before attributing the cause of this symptom to PAD (80). 
Rest pain- According to John Cranley ischaemic rest pain is the pain that occurs over 
the toes and metatarsal heads at rest. Occasionally, the pain occurs proximally. The 
pain is usually aggravated on elevation or at horizontal position and is relieved in a 
dependent position(85). As opposed to claudication, pain may be relieved on walking 
as it increases local perfusion due to gravity. Chronic ischaemia can lead to ischaemic 
neuropathic pain which may present as burning, throbbing or shooting pain of the 
lower limbs. 
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Ischaemic Ulcers - Minor trauma can lead to small ulcers which worsen due to poor 
blood supply that does not meet the requisite demands of the healing tissue. These 
ulcers may also start out as pressure sores. The ulcers may themselves get infected and 
may also end up causing osteomyelitis in the underlying bone. Prompt recognition and 
treatment of an ischaemic ulcer are essential in saving the tissue. 84% of limb 
amputations were as a result of ulceration (86). 
Gangrene - Ischaemia tends to alter skin colour. Pallor or blackening of the skin can 
both occur. This will lead to necrosis and may spread to the deeper tissues also. 55% 
of all limb amputations in diabetics could be attributed to gangrene (86). 
Diagnosis of PAD 
In 1962, the WHO/Rose questionnaire was developed as a screening tool for PAD. It 
was noticed to have a high specificity (90%-100%) but low sensitivity (60%-68%) 
(87). 
The Edinburgh Claudication questionnaire was found to be more sensitive (91.3% 
[95% CI 88.1-94.5%]) and equally, if not more, specific (99.3% [95% CI 98.9-
100%]). It also had good repeatability (ĸ = 0.76, p<0.001) after 6 months (87). 
However, the sensitivity and specificity are based on the physician’s diagnosis and not 
necessarily using a gold standard method such as an angiogram. The Edinburgh 
Claudication questionnaire has been used in this study to diagnose symptomatic PAD.  
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Physical examination 
*Appearance of the peripheries- Prolonged inadequate blood flow to the extremities 
may cause thinning of the skin which becomes dry, shiny and devoid of hair (79). The 
nails may be brittle and disfigured. 
*Skin Temperature is a good indicator of decreased perfusion. The affected limb will 
be cool and demarcation of the warmth can help in assessing the extent and location of 
the occlusion. However, it may be confounded if both limbs are affected 
*Skin Colour- Buerger’s test is a serviceable adjunct to routine assessment of PAD 
(88). In this test, the lower limb is elevated above the level of the central venous 
pressure usually around 25 cm. This drains the deoxygenated blood from the 
peripheries and provides a valid assessment of the arterial blood flow. A normal limb 
will remain pink. However, an affected limb may become pale or dusky and a return 
to normal colour may take more than 20 s. 
*Ulcers- Ischaemic ulcers are most frequently seen on the tips of the toes and the 
intertriginous areas between the toes. It may also be seen in focussed areas where 
there is increased pressure like the head of the metatarsals and the lateral malleoli. 
*Gangrene- Both dry and wet gangrene may be seen in PAD. Dry gangrene is more 
common in PAD and there is a clear demarcation between the necrotic tissue and the 
viable tissue. Wet gangrene is a surgical emergency and should be dealt with 
appropriately at the earliest. 
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*Pulse- Palpation of the peripheral pulses is absolutely essential in any patient 
suspected to have PAD. At the very least the brachial pulse, radial pulse, posterior 
tibial artery pulse and dorsalis pedis pulse should be assessed (78). 
Non-invasive diagnostic tests for PAD 
History and examination of suspected PAD patients have to be corroborated with 
further investigations as independently clinical examination may not be sufficient 
proof to rule in, or rule out PAD (89). 
Ankle-Brachial Index (ABI) is a simple, relatively inexpensive and accurate method 
of diagnosing PAD by assessing the ratio of systolic blood pressures in the upper and 
lower limbs using a Doppler ultrasonography apparatus (90).  ABI predicts sites of 
occlusion found in angiography more accurately than just history and examination 
(83).  
Using an ABI evaluation was found to be justified (ROC area 0.95+/-0.02) for 
detecting significant PAD (>50% occlusion)(91). This translated to a sensitivity of 
79% and a specificity of 96% with an ABI cut off of 0.90. 
The ACC/AHA guideline for the management of peripheral arterial disease patients 
(2005) prescribes computing ABI by dividing the higher of the two ankle systolic 
pressures to the higher of the two brachial systolic pressures (83). 
 
Ankle Brachial Index (ABI) =
Higher Ankle Systolic Pressure
Higher Brachial Systolic Pressure
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The interpretation of ABI according to the ACC/AHA guidelines are as follows (83),  
Table 3.2     ACC/AHA (2011) interpretation of ABI 
ABI Interpretation 
>1.30 Non-compressible 
1.00-1.29 Normal 
0.91-0.99 Borderline 
0.41-0.90 Mild to Moderate PAD 
0.00-0.40 Severe PAD 
 
An ABI cut-off of <0.90 has been found to be 95% sensitive and 99% specific in 
identifying angiogram positive cases of PAD (92). 
An ABI measurement of more than 1.30 is also strongly indicative of PAD. It has to 
be corroborated with a Toe-Brachial index. A higher ABI (>1.30) is considered 
predictive of systemic atherosclerosis and may indicate a higher risk of a 
cardiovascular event (35). 
Higher ABI was found to increase risk of foot ulcers and neuropathy as well has 
having a poorer Quality of Life as against people with normal ABI (93). 
Advantages of ABI: 
• High Specificity  
• Easy to perform 
• Relatively inexpensive 
• Can be done in a community set-up without many hassles 
• Not time consuming 
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Disadvantages of ABI: 
• Accurate values may not be arrived at in patients with non-compressible 
arteries 
• A few studies have shown low sensitivity resulting in higher false negative 
rates (94). 
Toe-Brachial Indices: Toe pressure index is arrived at by measuring the systolic 
pressure at the toes. It is an extremely useful method as it can be used in patients with 
non-compressive arteries. Non-compressive arteries are very common among 
diabetics and the elderly who also form the majority of the population at risk for PAD. 
A toe brachial index of <0.7 is diagnostic of lower limb PAD (83). 
Digital perfusion can be measured and hence even small artery disease maybe picked 
up by TBI. The equipment may be difficult to handle and the personnel should be 
appropriately trained. It may not be feasible to carry out a community based screening 
using TBI as the reading requires expert technique and careful handling to preserve 
accuracy. 
Angiography: Contrast angiography (Digital Subtraction Arteriography) is the 
definitive method for evaluation of peripheral vessels. CT angiogram and MR 
angiogram are also useful tools in diagnosis of PAD (95). 
Other Methods of Diagnosis (96) 
• Segmental pressure examination 
• Pulse Volume recording 
• Doppler Ultrasound 
 28 
 
Natural history of the disease 
 Peripheral Arterial Disease presents with a wide array of symptoms which depends 
on the location and extent of atherosclerosis in the peripheral arteries and can range 
from mild calf pain on walking, to limb-threatening ischaemia.  
A longitudinal study done on 403 patients to identify risk factors for progression of 
the disease, showed current smoking was a major risk factor. Elevated CRP, 
lipoprotein (a) and total cholesterol by HDL levels were also found to be associated 
with progression of disease in large vessels. In small vessel PAD, diabetes was found 
to be the prime risk factor(97). In a multi-ethnic study on atherosclerosis, ABI was 
measured 3 years apart on subjects from a varied ethnicity. In the study men and 
people with higher BMI were found to have a higher risk of having a high ABI 
(>=1.4) which is suggestive of intravascular calcification and atherosclerosis. African-
Americans were found to be at a higher risk of having low ABI(<0.9) which indicates 
limb ischaemia (98). Thus, ethnicity, gender and BMI were found to be factors in the 
progression of the disease.  
A systematic review of 35 studies with follow up periods ranging from 1 to 13 years 
was done and it found similar predictors of disease progression as mentioned above. 
In the follow-up period, it was found that 7% of asymptomatic patients developed 
Intermittent Claudication. Also, 21% of patients who had previously had intermittent 
claudication had developed critical limb ischaemia with 4%-27% of the patients 
ending up with an amputation (99). A population-based cohort study on 6915 PAD 
patients found that there was no significant difference between the two sexes as far as 
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the progression of peripheral arterial disease was concerned. However, men with PAD 
were found to be at a higher risk of having a myocardial infarction (adjusted 
HR=1.15) (100).  In a study done on 59 ex-servicemen who were diagnosed to have 
PAD before the age of 45, it was found that 71% of them had significant (more than 
50%) coronary artery disease. During the time of the study, five of the participants 
died. Four of them died due to acute coronary syndrome and one of them had a stroke 
(101). 
A cross-sectional study was done among 416 patients with PAD. They were screened 
for internal Carotid artery disease. Major Internal Carotid Artery Disease (MICAD) 
(>75% obstruction) was seen in 14.9% of patients with PAD (102). This proportion of 
carotid artery disease was significantly higher than the proportion of patients with an 
aneurysm who have carotid artery disease (p<0.05) (102). 
A majority of patients with PAD are unaware of their disease. More than half the 
patients with the condition are aware that they have the disease. Physicians pick up 
only 30% of the patients with PAD that they see (103). 
In a prospective cohort study done among 6880 people above the age of 65 12.1% 
were found to have asymptomatic PAD. A further 8.6% had symptomatic PAD. PAD 
was found to be a strong predictor of all-cause mortality as well as severe vascular 
events (104).  The PAD Awareness, Risk and Treatment: New Resources for Survival 
(PARTNERS) study was a multi-centre cross-sectional study done among  6979 
patients who were either over 70 years of age or high-risk population (diabetics, 
smokers) between the ages of 50 and 69. 29% of these people had PAD. 13% had 
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PAD only while 16% had PAD and coronary artery disease. 47% had neither PAD nor 
CAD. Among patients with PAD, classic claudication was rare and seen only in 11% 
of the subjects. Interestingly 83% of patients with PAD at the time of recruitment 
knew that they had the disease but less than half (49%) their physicians knew about 
the diagnosis (81). 
The Reduction of Athero-thrombosis for Continued Health (REACH) registry is an 
international, prospective, cohort study. Its database includes 68,000 patients who 
have been confirmed to have vascular disease(105). The following figure is based on 
the REACH data.  
Fig 3.2 Overlap of atherosclerostic vascular diseases (106) 
 ) 
Source: Journal of Vascular Surgery Volume 45, Issue 1, Supplement, January 2007, 
Pages S5-S67 (106). 
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A longitudinal cohort study done in Minnesota among 50-70-year-old people with 
PAD, Diabetes or both showed that a decrease of 0.1 ABI had a 13% increase in the 
risk of death(62). A systemic review showed that PAD is an indicator of extensive 
atherosclerotic disease. It showed a 150% increase in the risk of mortality among 
patients with claudication (33). A graph showing the survival rate is shown below. 
Fig 3.3 Survival rate in patients with Claudication (107) 
 
Source: Journal of Vascular Surgery Volume 45, Issue 1, Supplement, January 2007, 
Pages S5-S67 (107) 
In the above graph, IC stands for Intermittent Claudication, CLI stands for Critical 
Limb Ischaemia.  
The Minnesota study also showed that the relative hazard of mortality in patients with 
Diabetes and progressive PAD was 2.29 times as that of diabetics without PAD (62). 
The original cohort of the Framingham Heart Study was followed up for 38 years and 
381 people who previously had asymptomatic PAD developed intermittent 
claudication. Cigarette smoking, diabetes, hypertension, age and dyslipidaemia were 
found to be associated with the progression of the disease (46). 
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In a concurrent cohort study done among 1244 men with claudication, over a period of 
15 years with a mean follow-up of 45 months, the cumulative risk of a person with 
claudication developing rest pain and ulceration over a 10 year period was 30% and 
23% respectively. The study also inferred that diabetes mellitus and ABI were the 
only significant predictors for both ischaemic rest pain and ulcers (108). 
A study done in Australia among 456 patients with intermittent claudication estimated 
a 5-year risk of amputation as 6.2% among patients who underwent early 
revascularization and 0.7% among patients who were managed conservatively initially 
(p=0.003) (109).  A critical review of PAD among people over 50 years of age 
showed that 70%-80% of patients with intermittent claudication developed stable 
claudication within 5 years. A further 20% had a non-fatal cardiovascular event, 
including acute coronary syndrome and cerebrovascular accidents. The claudication 
worsened in 10%-20% of the patients and 1%-2% even developed critical limb 
ischaemia. 15%-30% of the people died within 5 years and three-fourth of the 
mortality was because of cardiovascular events (77,110). Another study showed that 
patients who had severe impairment due to pain while climbing stairs had a higher risk 
of all-cause mortality(Hazard ratio: 1.70; CI: 1.08-2.66) and cardiovascular system 
related deaths(Hazard ratio: 3.11; CI:1.30-7.47) than those with lesser impairment 
(111). 
A study done among 109 symptomatic patients in Germany followed them for an 
average period of 104 months. 28 (25.7%) of the participants passed away and 10 
(9.2%) of them died due to cancer. This amounts to 36% of the total all-cause 
mortality among symptomatic PAD patients. This can be explained by the high 
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prevalence of smokers among patients with PAD which may be the actual cause of the 
malignancy (112). 
A cross-sectional study done among 423 people with PAD in Chicago estimated a 
prevalence of depression among PAD patients as 21.7% and was associated with 
increased impairment(113).  Symptoms and subsequent impairment were also 
associated with poorer quality of life among older individuals in a cross-sectional 
study done among eighty symptomatic patients (114). 
Critical limb ischaemia is manifested as ulcers or resting pain in the peripheries. Of all 
patients with symptomatic PAD 1%-2% patients have critical limb ischaemia. 
According to a systematic review, 21% of patients with intermittent claudication 
progressed to critical limb ischaemia(99). Smoking, dyslipidaemia and diabetes were 
found to be the major risk factors associated with critical limb ischaemia. Diabetes 
and ABI were found to be good predictors of the disease (97,108). In a review of 20 
publications of 6118 patients with critical limb ischaemia, the cumulative mortality 
rate was 26%, 44% and 56% at 1 year, 3 years and 5 years respectively. Patients were 
classified as critical and sub-critical based on symptoms and ankle pressure in this 
study. 27% of patients in the low-risk group (only rest pain and ankle pressure > 40 
mmHg) did not have an amputation after being managed conservatively. However, in 
the high-risk group (peripheral ulcers or ankle pressure < 40 mmHg) 95% of patients 
managed conservatively ended up with an amputation as opposed to only 25% who 
underwent arterial reconstruction (115). According to a non-concurrent cohort study, 
the amputation rates were higher (17% v 3.9%, p value= 0.02) among people who had 
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early onset of atherosclerosis in their peripheral arteries than the cohort with older 
people. The overall outcome was also found to be poorer (116). 
Insulin resistance was also found to be associated with PAD and the progression of 
disease in older adults (117). The POPADAD (Prevention of Progression of Arterial 
Disease and Diabetes) trial was a multi-centre randomised control trial and it showed 
that 16% of 1276 asymptomatic patients with either Type 1 or Type 2 diabetes 
developed intermittent claudication at six years. Critical limb ischaemia was seen in 
3% of the patients and 1.6% ended up with a major limb amputation. The study 
primarily found that aspirin and anti-oxidants have no role in influencing the 
progression of the disease (118). 
 
2. Chronic Venous Disease (CVD) 
Chronic Venous Disease/Disorders refer to the entire spectrum of functional or 
morphological abnormalities of the venous system (119). These disorders have been 
associated with significant morbidity and mortality.  
Varicose veins are the most common and recognisable form of venous disease. 
Varicose veins are subcutaneous veins that are dilated ≥3 mm in diameter while the 
person is in an upright position (17). The Great Saphenous Vein (GSV) and the Small 
Saphenous Vein (SSV) are the most frequently affected veins. Lesser recognized 
forms of venous disease are telangiectasia, ankle oedema secondary to poor venous 
drainage, eczema, lipodermatosclerosis and healing or non-healing ulcers. 
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Chronic Venous Insufficiency is a term used to describe the severe forms of venous 
disease. Ankle oedema, skin changes and ulcers due to venous disease are all 
classified as chronic venous insufficiency (119). 
Pathophysiology of the disease 
Retrograde venous blood flow for an abnormal period of time is called Venous 
Reflux. It can be due to idiopathic or congenital dysfunction/absence of valves. 
Trauma and thrombosis are two other major factors resulting in venous reflux. 
Pregnancy is another reason for venous reflux which may ultimately lead to 
varicosities. 
Labropoulos et al. have concluded that the development of venous reflux is mostly 
due to a local process. This is most likely due to a weakness in the vessel wall. This 
issue can be multifocal, thereby resulting in venous disease in more than one place 
(120). 
Bicuspid venous valves are present throughout the peripheral venous system directing 
the blood flow from distal to proximal and superficial to deep, except in the foot 
(121). Any pathology in these valves, either congenitally or due to trauma, thrombosis 
et cetera will cause backflow resulting in either venous congestion or deep venous 
thrombosis. 
Lower muscle strength is also very important for the normal functioning of the venous 
system. People with chronic venous disease were found to have impaired lower limb 
muscle strength (122). The muscles, mainly the calf and the thigh muscles play an 
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important role in the circulation of venous blood as they serve as a pump that pushes 
the blood against gravity. 
Various studies have shown that varicose veins are not because of thin walls but 
because of wall thickening in response to venous hypertension. This causes an 
increased production of collagen, proliferation of smooth muscle cells and elastin. It 
was also found that there is an abnormal accumulation of extracellular matrix in 
venous disease (123–125). The breakdown of the vascular extracellular matrix leads to 
increased vascular permeability leading to oedema. 
The RBCs migrate from the vascular space into the tissues and subsequently degrades 
in the tissue leading to extravasation of iron and ferritin. This results in the 
characteristic discolouration of the skin specifically in the gaiter area of the leg (126). 
Studies have shown that there is an increased accumulation of mast cells around the 
vessels in chronic venous disease leading to increased collagen accumulation and 
fibrosis (127). There is also increased permeability of the vessels leading to 
surrounding oedema (128). Together they cause severe fibrosing inflammation of the 
subcutaneous fat (Panniculitis) which binds the skin to the subcutaneous tissue. This 
condition is called Lipodermatosclerosis. 
The accumulation of matrix metalloproteinases (MMP) leads to ulcer formation which 
is non-healing in nature. These end up as chronic ulcers (129). 
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Epidemiology 
A cross-sectional survey done in Edinburgh among 1566 subjects between the ages of 
18 and 64 found a prevalence of Chronic Venous Insufficiency of 9% among men and 
7% among women (p value<0.05) (130). 
A cross-sectional study done in Italy among adult men (mean age 59.1) and women 
(mean age 50.4) showed a prevalence of telangiectasia among 14.7% asymptomatic 
women and 8.9% asymptomatic men (131). The same study estimated a prevalence of 
varicose veins at 15.1% among asymptomatic women and 8.0% among asymptomatic 
men. 
A study done in the USA showed that the prevalence of varicose veins among Asians 
in the US was 18.4% above the age of 40 (132). 
A study done in Perth, Western Australia, showed a prevalence of chronic venous 
ulcers as 0.62 per 1000 population (133). 90% of people with ulcers were found to be 
above the age of 60, who comprised 16.7% of the general population. 
Risk Factors 
Male gender, increasing age, obesity and a history of leg trauma were all found to be 
significant risk factors for CVD (134). 
Obesity: Overweight and obesity has been found to be a major risk factor for venous 
disease (135–137). The Edinburgh Vein study showed 2.1 times (95% CI 1.0-4.4) 
higher risk of developing reflux in overweight patients (138). The Mean BMI was 
found to be higher in the group with superficial reflux (26.2kg/m², 95% CI 25.5-27.0) 
than in normal subjects (25.2 kg/m², 95% CI 24.8-25.6) (139). 
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A group of 104 healthy post-menopausal women between the ages 48-64 were chosen 
from the DIANA (DIet and ANdrogens) project and assessed for venous disease. It 
was found that a BMI of more than 30 in these women was significantly associated 
with venous disease (OR 5.8, 95% CI 1.2-28.2) (140). 
Trauma: A case-control study done in the USA showed that a previous history of 
trauma or inflammation of the vessels (phlebitis) was found to be significantly 
associated with the development of chronic venous disorders (OR 2.4 and 25.7 
respectively) (134). 
Pregnancy: Previous pregnancy has been an established risk factor for venous reflux 
(139). Both hormonal and hydrostatic reasons are attributed to this. It is reckoned that 
new varicose veins develop in 28% of all pregnancies. This increases with each 
subsequent birth (141). Increased number of childbirths were associated with a higher 
risk of CVD(136).  The San Diego Population study estimated a risk of chronic 
venous disease at 1.14 (95%CI 1.05-1.23) per birth (142). 
Gender: A cross-sectional study done in Serbia showed a higher prevalence of venous 
disease among women than in men. However, the proportion of more severe form of 
the disease was significantly higher among the men (136). This was corroborated by 
the San Diego Population study where venous disease was more prevalent among 
women though the men had more frequent advanced disease (142). Another study 
showed that visible venous disease may be seen in 20%-25% of women but only in 
10%-15% men (143). 
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Height: The Edinburgh Vein study revealed that increased height proved a significant 
risk factor for Venous Disease (OR 1.13, 95% CI 1.02-1.26) (139). A cross-sectional 
study done in rural Maharashtra showed by linear regression analysis that increased 
height contributed to a 12.9% increase in the saphenous vein diameter in the supine 
position. Height was also found to cause an 11.9% increase in diameter during 
Valsalva manoeuvre in people with chronic venous insufficiency (144). 
Genetic predisposition: Hereditary factors have been known to predispose venous 
disease (135). A study done in France has shown a prevalence of venous disorders in 
90% of people for whom both the parents have venous disease. The proportion 
becomes 25% in men and 62% in women for whom only one parent had venous 
disease and 20% of people whose parents did not have the disease (145). 
A genetic study of chronic venous congestion was conducted in Italy. This study 
identified a marker on chromosome 16q24 which may be related to the development 
of varicose veins (146).  
Varicose veins have been associated with Klippel-Trenaunay Syndrome (congenital 
defective/absence of venous valves), Lymphedema-distichiasis syndrome (associated 
with FOXC2 gene mutation), Cerebral Autosomal-Dominant Arteriopathy with 
Subcortical Infarcts and Leukoencephalopathy (CADASIL) (associated with Notch3 
gene mutation), Chuvash Polycythaemia (an autosomal recessive disease caused due 
to a mutation in the von Hippel-Lindau gene in chromosome 3p25) and various other 
genetic disorders (147). 
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Clinical Presentation 
History 
An entire spectrum of symptoms can be seen in chronic venous disease. The most 
common ones are: 
• Lower limb pain/discomfort 
• Muscle cramps 
• Pruritus  
• Skin changes (hyperpigmentation, dryness) 
• A Feeling of heaviness in the lower limbs 
• Swelling of the lower limbs 
• Non-healing ulcers 
Physical Examination: 
Telangiectasia/reticular veins- Telangiectasia is a confluence of intradermal venules 
<1 mm in diameter. They are the most commonly seen manifestation of venous 
disease. Reticular veins are dilated subdermal veins 1 mm-3 mm in size (131). 
Varicose Veins- These are serpentine, dilated subcutaneous veins >3 mm in diameter. 
They are the most recognisable form of venous disease. 
Oedema- Unilateral oedema in association with venous malformations should lead to 
a high suspicion of venous insufficiency. It is limited to the extremities and decreases 
on lying down. Diuretics may not be helpful in this setting and may even lead to hypo-
perfusion. 
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Skin changes- As discussed previously, the breakdown of the extravasated RBCs lead 
to deposition of hemosiderin in the subcutaneous tissue leading to pigmentation. This 
pigmentation is usually seen around the medial malleolus. 
Avascular fibrosis leads to Atrophie Blanche, which are hypo-pigmented spots which 
are prone for ulceration in the future. Atrophie Blanche is again commonly seen 
around the medial aspect of the ankle. 
Lipodermatosclerosis- As mentioned earlier, chronic venous congestion causes 
fibrosing panniculitis of the subcutaneous tissue leading to induration causing 
lipodermatosclerosis. This starts off locally but progresses and involves the entire 
lower limb circumferentially. 
Chronic Venous Ulcers: Venous ulcers are the common ending point of severe chronic 
venous congestion. A study done in Brazil showed that age above 60 years was found 
to have 4 times the risk of developing a non-healing venous ulcer. Extensive 
lipodermatosclerosis was found to have an 8.7 times higher risk while previous ulcers 
were attributed a whopping 19.9 times risk of developing a recurrence (148). 
They are usually seen in the Gaiter area. They can occur elsewhere in the leg if there 
is preceding trauma. But chances of ulceration above the knee and in the forefoot are 
extremely rare. There may be more than one ulcer. Venous ulcers exhibit exquisite 
tenderness, are shallow, have a granulation base and are exudative. The ulcer borders 
are irregular but well demarcated. 
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The CEAP classification is used for diagnosing and classifying chronic venous 
disorders. Physical examination is hence an important part in the diagnosis of the 
disease. 
The revised CEAP (Clinical, Etiologic, Anatomic and Pathophysiologic) classification 
of venous disease is described below (149). 
 
Clinical Classification 
C0- No physical signs of venous disease 
C1- Reticular veins or telangiectasia 
C2- Varicose veins 
C3- Ankle Oedema 
C4a- Eczema or hyperpigmentation 
C4b- Atrophie Blanche or Lipodermatosclerosis 
C5- Healed Ulcer (Venous) 
C6- Active Ulcer (Venous) 
S- Symptomatic (as listed above) 
A- Asymptomatic 
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Etiologic Classification: 
Ec- Congenital 
Ep- Primary 
Es- Secondary (post trauma/thrombosis) 
En- No identifiable venous cause 
Anatomic Classification: 
As- Superficial veins 
Ap- Perforators 
Ad- Deep veins 
An- No identifiable venous locations 
Pathophysiologic Classification: 
Pr- Venous Reflux 
Po- Venous Obstruction 
Pr, o- Venous reflux and obstruction 
Pn- No identifiable venous pathophysiology 
Diagnosis 
The diagnosis of venous disorders is mainly clinical. The CEAP classification is used 
for diagnosis as well as classification.  
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Venous reflux is diagnosed by duplex ultrasound by measuring the duration of 
retrograde flow. Labropoulos et al. defined the cut off for venous reflux as a reversed 
flow of more than 500 ms in the calf veins (both superficial and deep) and more than 
1000 ms in the more proximal femoropopliteal veins(150). 
Duplex ultrasound helps in identifying the nature of reflux and also the geography 
(superficial, perforator or deep vein). This helps in planning management. 
Definition of complications: 
Complications are classified as major and minor based on the following factors(152). 
Minor Complications- 
• No treatment, no long-lasting consequences 
• Nominal treatment, overnight hospital stay 
Major Complications- 
• Requires treatment, short-term hospital stay (<48 hours) 
• Requires major intervention, long-term hospital stay (>48 hours) 
• Adverse sequelae with permanent effect 
• Death 
 
Assessment of Severity: The severity of venous disease can be ascertained by the 
scores described in the following table (151). 
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Table 3.3     Revised Venous Clinical Severity Score 
 None- 0 Mild- 1 Moderate- 2 Severe- 3 
Pain/Discomfort  
Occasional (not 
restricting daily 
activities) 
Daily pain 
(restricting but 
not preventing 
daily activities) 
Daily pain 
(limits regular 
daily activities) 
Varicose veins 
(≥3mm in 
standing 
position) 
 Few, scattered 
Affects calf OR 
thigh 
Affects calf 
AND thigh 
Venous Oedema  
Restricted below 
the ankle 
Above the 
ankle but below 
the knee 
Extends above 
the knee 
Skin 
pigmentation 
(presuming 
venous origin) 
None or 
focal 
Limited to the 
peri-malleolar 
region 
Diffuse, but 
below the lower 
third of the calf 
region 
Widely 
distributed, 
involving the 
upper third of 
the calf region 
Inflammation   
Limited to the 
peri-malleolar 
region 
Diffuse, but 
below the lower 
third of the calf 
region 
Widely 
distributed, 
involving the 
upper third of 
the calf region 
Induration  
Limited to the 
peri-malleolar 
region 
Diffuse, but 
below the lower 
third of the calf 
region 
Widely 
distributed, 
involving the 
upper third of 
the calf region 
Active Ulcer 
number 
0 1 2 ≥3 
Active Ulcer 
duration 
 <3 months 
3 months-1 
year 
>1 year 
Active Ulcer 
size 
 Diameter <2 cm 
Diameter 2cm-
6 cm 
Diameter >6 
cm 
Compression 
therapy 
Not used Intermittent use 
Used on most 
days 
Full 
compliance 
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4. MATERIALS AND METHODS 
Study Setting 
The study was conducted in the Kaniyambadi block, Vellore District, Tamil Nadu, 
India. There are 82 villages in Kaniyambadi block and it and has a population of over 
one lakh twenty thousand people. The Community Health and Development (CHAD) 
program run by the department of Community Health, Christian Medical College 
(CMC),Vellore is located in Bagayam. The Government Vellore Medical College 
(GVMC) is in the Adukkamparai village of Kaniyambadi. There are also four 
peripheral health centres (PHCs) located within the block in Kammavanpet, 
Kathalampet, Kaniyambadi and Sholavaram villages. Apart from these there are many 
private clinics and hospitals providing health care to the people of Kaniyambadi 
block.  
The study was done in 4 villages, namely Munjurpet, Kattuputhur, Veppempet, and 
Kaniyambadi Puthur. These villages were chosen as they had the largest population 
among all the villages in each PHC area. 
The CHAD programme has been functioning in Kaniyambadi block for over 40 years. 
It provides primary and secondary care and is at close proximity to two 
tertiary/quaternary care centres (CMC and GVMC). CHAD operates based on a 
pyramid system. At the base of the pyramid are the Part Time Community Health 
Workers (PTCHWS) who are local villagers who provide a vital liaison between the 
community and the health system. Each village has a PTCHW and they report to a 
Health Aide. The Health Aide is a qualified Auxiliary Nurse and Midwife (ANM) 
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who cover 3-5 villages, which accounts to a population of 5000-7000. All vital events 
births to deaths, marriages to pregnancies are documented and reported by the Health 
Aides to the Public Health Nurses (PHNs). The PHNs visit the villages weekly and 
have a record of all pregnancies and an immunization register. A list of patients with 
Non-communicable disease is also maintained and updated regularly by the Health 
Aides in conjunction with the PHNs. Each village is visited once in 4 weeks by the 
area doctor (usually a PG registrar) and health care is provided in the village. This 
ensures an efficient system of record maintenance and enables proper follow-up of 
patients. It is in this resource rich setting that this study was embarked upon as there 
was a veritable void in knowledge of peripheral arterial disease in the community. The 
following is a map of Kaniyambadi. 
Fig 4.1 Map of Kaniyambadi 
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Study Design 
This study was a community based cross sectional study. 
 
Study Population 
Inclusion Criteria: Adults above the age of 18 years who were permanent residents of 
Kaniyambadi Block, Vellore and were willing to participate in the study. 
Exclusion criteria: Bilateral upper/lower limb amputees/absence of limbs 
 
Study Variables 
Peripheral arterial disease was diagnosed by measuring the Ankle-Brachial Index 
(ABI). ABI was measured using a handheld Doppler apparatus and an aneroid 
sphygmomanometer.  
 
Steps of measuring ABI 
• The participant was made to lie supine on a flat surface (floor/cot). 
• Systolic BP reading was measured in all 4 limbs using the aneroid 
sphygmomanometer and a Doppler apparatus. 
• The highest recorded reading in the lower limb was divided by the higher 
reading between the upper limbs to arrive at the ABI. 
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The diagnostic criteria are as below: 
Table 4.1 ACC/AHA ABI Interpretation guidelines 
ABI Interpretation 
>1.30 Non-compressible 
1.00-1.29 Normal 
0.91-0.99 Borderline 
0.41-0.90 Mild to Moderate PAD 
0.00-0.40 Severe PAD 
<0.90 and >1.30 were considered abnormal ABI and probable PAD. 
 
Chronic Venous Disorders were diagnosed and classified based on the CEAP 
(Clinical, Etiology, Anatomy, and Pathophysiology) classification. The Clinical 
Classification is as follows (149), 
• Class 0 – No visible or palpable signs of venous disease 
• Class 1 – Telangiectasia, reticular veins, malleolar flare 
• Class 2 – varicose veins 
• Class 3 – Oedema without skin changes 
• Class 4 – 4a) hyperpigmentation, venous eczema, 4 b) lipodermatosclerosis 
• Class 5 – Skin changes with healed ulceration 
• Class 6 -  Skin changes with active ulceration 
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Exposure variables 
• Smoking 
• Alcohol 
• Gender 
• Diabetes Mellitus 
• Systemic Hypertension 
• Education 
• Occupation  
• Socio-economic Status 
• Race 
• HbA1C, Creatinine, Lipid 
profile 
The data was collected using the following sources.  
Table 4.2 Sources of data 
Data Sources 
Smoking 
Alcohol 
Gender 
Age 
Diabetes Mellitus 
Systemic Hypertension 
Education 
Socio-economic Status 
Obesity 
Semi-structured, pilot tested 
questionnaire to collect data on socio 
demography and risk factors of the 
disease 
Chart Review was done to confirm 
medical history. 
Ankle Brachial Index 
Handheld Doppler ultrasound probe, 
Aneroid 
Sphygmomanometer 
Chronic Venous Disorder Clinical examination 
Haemoglobin, serum creatinine, 
Lipids, HbA1C 
Blood investigations 
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Socio Economic Status was calculated using the BG Prasad scale January 2018. The 
BG Prasad scale uses per capita family income per month to classify SES as follows: 
• Upper class : ≥ ₹ 6528 
• Upper Middle class: ₹ 3264 - ₹ 6527 
• Middle class: ₹ 1959 - ₹ 3263 
• Lower middle class: ₹ 979 - ₹ 1958 
• Lower class: ≤₹ 978 
The cumulative dose of cigarette smoking was expressed as pack-years. One pack-
year was regarded as the equivalent of 20 cigarettes smoked per day for one year 
(153). 
The definition of a standard drink varies from nation to nation. In India, 10 mL of 
absolute alcohol is considered a standard drink. The classification based on the 
strength of alcohol is given below (154), 
Table 4.3 Standard drink in India 
Type Percentage of Alcohol  Quantity (mL) 
Champagne 13 100 
Wine 13 100 
Fortified Wine 20 60 
Light Beer 2.7 425 
Regular Beer 4.9 285 
Spirit 40 30 
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Body Mass Index was calculated and classified according to the WHO Asia-Pacific 
classification, 
Table 4.4 WHO Asia/Pacific Classification of BMI 
BMI Classification 
<18.5 Underweight 
18.5-22.9 Normal 
23.0-24.9 Overweight 
≥25 Obese 
 
Study Tools 
• An Aneroid Sphygmomanometer is a device used to measure blood pressure, 
composed of an inflatable cuff to collapse and then release the artery under the 
cuff in a controlled manner and a mechanical manometer to measure the 
pressure. 
• A weighing scale was used for measuring weight that uses gravity as the 
primary source of resistance and a combination of simple machines to convey 
that resistance to the person using the machine 
• A height rod is a standardized instrument used for measuring the height of 
subjects 
• A Semi-structured, pilot tested questionnaire was used to collect data on socio 
demography and risk factors of the disease. It has been attached in the 
Annexure. 
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Sample Size Calculation 
The prevalence of PAD has been estimated to be anywhere between 3% and 7% in the 
general population (155). The sample size was therefore calculated using prevalence 
as 3%. 
p = 3; q= 97 
Absolute precision, d = 1.5 
 n=4pq/d2 =517 
Design effect = 2 x n 
Therefore, n= 1034 participants 
Sampling Technique 
A 2 stage cluster random sampling technique was used.  
• Four villages with the largest population in their respective PHC areas were 
chosen purposively.  
• Starting with the centre of the village, consecutive streets were selected. 
• All eligible members of the households in each street were taken until a sample 
of 300 people was attained in each village except one (Munjurpet) where 251 
participants were recruited. 
• If there was a member temporarily absent in a household the particular 
household was visited thrice before not including that person in the study. 
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Training in measurement of ABI 
 The investigator was trained in the vascular lab of the department of Vascular 
Surgery for 10 days in the technique of measuring ABI.  
 
Data entry and analysis 
Data was entered in Epidata v3.1.  
Analysis was carried out in SPSS v23.0. 
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5. RESULTS 
Sociodemographic profile: 
A total of 1151 individuals were included in the study. The distribution of the study 
population by age is described below. 
Fig 5.1 Sex distribution in the study population 
 
The majority of the study population (61%) were women. 
Table 5.1  Age distribution of the study population 
Age Group Frequency Percent 
<30 218  18.9 
30-39 220  19.1 
40-49 226  19.6 
50-59 207  18 
60-69 175  15.2 
70-79 80  7 
≥80 25  2.2 
Total 1151  100 
Most of the study population are between the age group 30-49 (38.7%) 
445, 39%
706, 61%
Sex
Male
Female
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Table 5.2    Description of study population by Religion 
Religion Frequency Percent 
Hindus 1098 95.4 
Muslims 33 2.9 
Christians 20 1.7 
Total 1151 100 
 The majority of the study population was Hindu. All the 33 Muslims were from one 
village (Veppempet). 
 
Age  
Mean (SD) = 46.01 
(16.36) 
Median (IQR) = 45 (26) 
Minimum = 18 
Maximum = 92 
N = 1151 
Fig 5.2 Age Distribution of the study population 
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Table 5.3   Description of the study population by Education 
Education Frequency Percent 
Nil 249 21.6 
Primary 176  15.3 
Middle 240  20.9 
High 247  21.5 
Higher Secondary 144  12.5 
Graduate / Post Graduate 84   7.3 
Professional / Honours 11 1.0 
Total 1151 100 
 
42.3% of the study population have completed high school education. 21.6% have 
never had formal education. 
Table 5.4  Description of the study population by Literacy 
Literacy Frequency Percent 
Illiterate 313 27.2 
Read Only 70 6.1 
Read And Write 768 66.7 
Total 1151 100 
 
From the above tables, the literacy rate corroborates with the level of education. 
27.2% of the study population were illiterate. 66.7% knew how to read and write. 
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Table 5.5   Description of the study population by Occupation 
Occupation Frequency Percent 
Unemployed 504 43.8 
Unskilled 330 28.7 
Semi Skilled 144 12.5 
Skilled 49 4.3 
Clerical/Shop Owner 86 7.5 
Semi-Professional 27 2.3 
Professional 11 1.0 
Total 1151 100 
 
Most of the study population were unemployed, possibly due to the high 
unemployment rates among women who constituted the majority of the subjects. 
Occupation was classified based on the Modified Kuppuswamy Scale January 
2017(156). 
Table 5.6  Description of study population by Family Type 
Family Frequency Percent 
Joint/Extended 463 40.2 
Nuclear 688 59.8 
Total 1151 100 
  
Almost 60% of the participants were part of a nuclear family. 
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Table 5.7  Description of Study Population by SES 
SES (BG Prasad Jan ’18) Frequency Percent 
Lower 
224   19.5 
Lower Middle 
398   34.6 
Middle 
295   25.6 
Upper Middle 
157  13.6 
Upper 
77   6.7 
Total 
1151  100 
The bulk of the study subjects were from the lower middle class (34.6%). There was a 
sizeable chunk of participants from the Middle class (25.6%) also. 
Table 5.8    Description of Study Population by Smoking Habits 
Smoking Frequency Percent 
Current 94 8.2 
Past 56 4.9 
Never 1001 87.0 
Total 1151 100 
All the 150 people with a history of smoking were men (33.7%).  
Table 5.9     Description of Study Population by Alcohol Consumption 
Alcohol Frequency Percent 
Current 199 17.3 
Past 46 4.0 
Never 906 78.7 
Total 1150  100 
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All 245 people who had or have been consuming alcohol were men (55.1%). None of 
the women smoked tobacco or consumed alcohol in their life. 
Table 5.10        Frequency of Oral Contraceptive Pills (OCP) use among women 
OCP Use Among Women Frequency Percent 
Yes 19 2.7 
No 687 97.3 
Total 706 100 
 
Table 5.11 Description of study population by the frequency of vegetable 
consumption 
Vegetable Consumption Frequency Percent 
Daily 1085 94.3 
Six times a week 0 0 
Five times a week 6 0.5 
Four times a week 0 0 
Thrice a week 3 0.3 
Twice a week 9 0.8 
Once a week 44 3.8 
Thrice a month 0 0 
Twice a month 0 0 
Once a month 3 0.3 
Less than monthly 1 0.1 
Total 1151 100 
Most of the study subjects consumed vegetables on a daily basis. 
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Table 5.12 Description of study population by the frequency of fruit 
consumption 
Fruits Frequency Percent 
Daily 261 22.7 
Six times a week 1 0.1 
Five times a week 5 0.4 
Four times a week 15 1.3 
Thrice a week 119 10.3 
Twice a week 301 26.2 
Once a week 252 21.9 
Thrice a month 15 1.3 
Twice a month 81 7.0 
Once a month 77 6.7 
Less than monthly 24 2.1 
Total 1151 100 
Fewer people consumed fruits daily (22.7%) than vegetables and 2.1% consumed 
fruits less than once a month  
Table 5.13   Median Intake of Fruits and Vegetables. 
Intake per Month Median (IQR) in Days 
Vegetable 30 (0) 
Fruits  8 (8) 
More than 50% of the people consumed fruits at least twice a week. 
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Description of Study Population based on Physical Characteristics such as Height, 
Weight and BMI 
 
Fig 5.3   Height distribution among the study population
 
 
N =1151 
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Fig 5.4 Weight distribution among the study population 
 
 
N=1151 
 
Table 5.14  Physical Characteristics of the study population 
 
Characteristics  Height Weight BMI 
Mean (STD DEV) 157.38 (0.276) 61.18 (14.11) 24.72 (5.20) 
Median (IQR) 157 (13) 60 (17) 24.39 (6.79) 
Minimum 131 31 12.98 
Maximum 186 151 56.14 
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Table 5.15   Description of the Study Population based on the Body Mass Index 
BMI (WHO Asia-Pacific) Frequency Percent 
Underweight (<18.5) 119 10.3 
Normal (18.50-22.99) 328 28.5 
Overweight (23.00-24.99) 193 16.8 
Obese (>25.00) 511 44.4 
Total 1151 100 
A large proportion - 44.4% of the study population fall under the obesity range. A 
further 16.8% were overweight. 10.3% were underweight leaving behind a measly 
28.5% of the population in the normal BMI group. 
Description of Study Population based on comorbid illnesses:  
Table 5.16  Prevalence of hypertension in the study population 
History of Hypertension Frequency  Percent 
Yes 168  14.6 
No 983  85.4 
Total 1151  100 
14.6% of our study population were known cases of hypertension.  
Table 5.17  Prevalence of diabetes mellitus in the study population 
History of Diabetes Mellitus Frequency  Percent 
Yes 141 12.3 
No 1010  87.7 
Total 1151  100 
The proportion of people with a history of Diabetes in our study population is 12.3%. 
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Table 5.18  Duration of comorbid illnesses 
Duration of illness in months among 
those previously diagnosed 
(by history) 
Median (IQR) 
Hypertension 36 (66) 
Diabetes 48 (83) 
 
The median history of the duration of hypertension was 36 months (3 years) and 
diabetes mellitus was 48 months (4 years). 
Table 5.19  History of Ischaemic Heart Disease in the study population 
Ischaemic Heart Disease Frequency  Percent 
Yes 15  1.3 
No 1136  98.7 
Total 1151  100 
 
1.3%  of the population have given a history of Coronary Artery Disease (CAD 
Table 5.20  History of Stroke in the Study Population 
Cerebrovascular Accident Frequency  Percent 
Yes 11 1 
No 1140  99 
Total 1151  100 
 
11 people (1%) of the study population have had a documented history of stroke in the 
past. 
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Table 5.21 Prevalence of Intermittent Claudication 
Claudication Pain Frequency Percent 
Yes 44 3.8 
No 1107 96.2 
Total 1151 100 
 
Prevalence of intermittent claudication in the study population was 3.8%. 
Table 5.22 Prevalence of  Chronic Venous Disorders (CVD) 
Venous Disease Frequency Percent 
Telangiectasia 24 2.1 
Varicose veins 52 4.5 
Ankle oedema 4 0.3 
Lipodermatosclerosis 3 0.3 
Healed ulcer 0 0 
Active ulcer 0 0 
No disease 1068 92.8 
Total 1151 100 
 
Chronic Venous Disease (CVD) was seen in 7.2% (95% CI 5.7%-8.8%) of the study 
population 
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Prevalence of Abnormal ABI in the Study Population 
Table 5.23  Prevalence of Peripheral Arterial Disease (PAD) 
ABI Frequency Percent 
<0.9 3 0.3 
0.9-1.3 1128 98.0 
>1.3 20 1.7 
Total 1151 100 
 
The Prevalence of Abnormal ABI in the study population has been estimated at 2% 
(95% CI 1.3%-3%). In a much smaller study done elsewhere, the prevalence of 
Abnormal ABI in normal individuals was 4%(157). 
ABI was also analysed as a continuous variable. It was a skewed distribution. 
Mean (Std. dev) = 1.07 (0.12) 
Median (IQR) = 1.06 (0.13) 
Minimum = 0.85 
Maximum = 2.42 
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Fig 5.5 Distribution of ABI among the study population. 
 
 
 
 
 
 
  
Percentiles 5 10 25 50 75 90 95 
ABI 0.92 0.95 1.0 1.06 1.13 1.20 1.25 
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Table 5.24 ABI by Age Groups 
 
Age Distribution 
(Years) 
ABI 
Total 
Abnormal Normal 
<30 
Frequency 3 215 218 
% 1.4 % 98.6 % 100.0 % 
30-39 
Frequency 2 218 220 
% 0.9 % 99.1 % 100.0 % 
40-49 
Frequency 1 225 226 
% 0.4 % 99.6 % 100.0 % 
50-59 
Frequency 4 203 207 
% 1.9 % 98.1 % 100.0 % 
60-69 
Frequency 7 168 175 
% 4.0 % 96.0 % 100.0 % 
70-79 
Frequency 5 75 80 
% 6.3 % 93.8 % 100.0 % 
≥80 
Frequency 1 24 25 
% 4.0 % 96.0 % 100.0 % 
Total 
Frequency 23 1128 1151 
% 2.0 % 98.0 % 100.0 % 
 
There was a gradual increase in the number of cases in the older population groups. 
Age group 70-79 contained the maximum proportion of people with probable PAD. 
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Socio-economic status V PAD: 
Middle SES was taken as the reference and each class of SES was cross-tabulated 
along with the Middle SES against PAD to look for any association. None of the 
groups had a significant association. There was no consistent pattern of increase or 
decrease in effect between the groups either. 
 
Table 5.25 ABI by Socio Economic Status 
SES  
(BG PRASAD JAN ’18) 
ABI OR 
(95% CI) 
P value 
Abnormal  Normal  
Lower 
Frequency 4 220 0.65 
(0.19-2.19) 
0.487 
% 1.8% 98.2% 
Lower 
Middle 
Frequency 6 392 0.55 
(0.19-1.60) 
0.265 
% 1.5% 98.5% 
Middle 
Frequency 8 287 
1.00 1.000 
% 2.7% 97.3% 
Upper 
Middle 
Frequency 3 154 0.70 
(0.18-2.67) 
0.601 
% 1.9% 98.1% 
Upper 
Frequency 2 75 0.96 
(0.20-4.60) 
0.956 
% 2.6% 97.4% 
Total 
Frequency 23 1128 
  
% 2.0% 98.0% 
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Nutritional Status, as understood by calculating the Body Mass Index (BMI), was 
cross-tabulated against PAD using Normal BMI as the reference. As has been already 
discussed, the WHO Asia-Pacific classification of BMI has been used to classify the 
study population. No significant association has been found. However, both 
undernutrition and overweight/obesity are identified as risk factors. 
 
Table 5.26 ABI by Nutritional Status  
Nutritional Status 
ABI OR  
(95% CI) 
P value 
Abnormal Normal 
Underweight 
Frequency 3 116 2.10  
(0.46 – 9.50) 
0.327 
% 2.5% 97.5% 
Normal 
Frequency 4 324 
1.00 1.000 
% 1.2% 98.8% 
Overweight 
Frequency 6 187 2.60  
(0.72-9.33) 
0.143 
% 3.1% 96.9% 
Obese 
Frequency 10 501 1.62  
(0.50-5.20) 
0.420 
% 2.0% 98.0% 
Total 
Frequency 23 1128 
  
% 2.0% 98.0% 
 
Consumption of Alcohol in the past has been found to be significantly associated with 
an abnormal ABI. People who have consumed alcohol in the past were found to have 
5.66 times the risk of having an Abnormal ABI than someone who has never 
consumed alcohol. 
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Table 5.27  ABI by Alcohol  Intake 
Alcohol Intake 
ABI OR  
(95% CI) 
P value 
Abnormal Normal 
Current 
Frequency 4 195 1.22  
(0.40-3.71) 
0.728 
% 2.0% 98.0% 
Past 
Frequency 4 42 5.66  
(1.80 – 17.79) 
0.001 
% 8.7% 91.3% 
Never 
Frequency 15 891 
1.00 1.000 
% 1.7% 98.3% 
Total 
Frequency 23 1128 
  
% 2.0% 98.0% 
 
Similarly, a past history of smoking tobacco confers a risk of 4.74 times than that of a 
non-smoker. 
Table 5.28  ABI by Smoking 
Smoking 
ABI OR 
 (95% CI) 
P value 
Abnormal Normal 
Current 
Frequency 3 91 2.03 
 (0.58-7.10) 
0.258 
% 3.2% 96.8% 
Past 
Frequency 4 52 4.74  
(1.53-14.67) 
0.003 
% 7.1% 92.9% 
Never 
Frequency 16 985 
1.00 1.000 
% 1.6% 98.4% 
Total 
Frequency 23 1128 
  
% 2.0% 98.0% 
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Table 5.29 BIVARIATE ANALYSIS FOR PAD 
Factors 
Abnormal 
ABI 
Normal ABI 
Odds Ratio 
(95% CI) 
P Value 
Sex 
Male 16 (3.7%) 429 (96.3%) 3.72 
(1.52-9.13) 
0.002 
Female 7 (1.0%) 699 (99%) 
Age 
≥60 13 (4.6%) 267 (95.4%) 4.19 
(1.82-9.67) 
<0.001 
<60 10 (1.1%) 861 (98.9%) 
Smoking 
Ever 7 (4.9%) 143 (95.1%) 3.01 
(1.219-7.45) 
0.012 
Never 16 (1.6%) 985 (98.4%) 
Diabetes 
Yes 7 (5.2%) 134 (94.8%) 3.25 
(1.31-8.03) 
0.007 
No 16 (1.6%) 994 (98.4%) 
Hypertension 
Yes 7 (4.3%) 161 (95.7%) 2.63 
(1.06-6.49) 
0.03 
No 16 (1.7%) 967 (98.3%) 
Fruit Intake 
Less Than Daily 18 (2.0%) 872 (98.0%) 1.06 
(0.39-2.88) 
0.914 
Daily 5 (1.9%) 688 (98.1%) 
Vegetable Intake 
Less Than Daily 2 (3.0%) 64 (97.0%) 1.58 
(0.36-6.90) 
0.537 
Daily 21 (1.9%) 1064 (98.1%) 
Alcohol 
Ever 8 (3.4%) 237 (96.6%) 2.01 
(0.84-4.77) 
0.110 
Never 15 (1.7%) 891 (98.3%) 
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Sex, Age, history of Diabetes, Hypertension and ever smoking were found to be 
significant risk factors for peripheral arterial disease in bivariate analysis. 
Table 5. 30 ABI by Alcohol consumption among men  
Alcohol among men 
ABI 
Total 
Odds Ratio 
(95% CI) 
P value 
Abnormal Normal 
Ever 
Frequency 8 237 245 
0.81 
(0.30-2.20) 
0.68 
% 3.3% 96.7% 100.0% 
Never 
Frequency 8 192 200 
% 4.0% 96.0% 100.0% 
Total 
Frequency 16 429 445 
 
3.6% 96.4% 100.0% 
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Table 5.31 COMPARISON OF MEANS WITH PAD PATIENTS (Part I) 
Exposure ABI N Mean 
Std. 
Deviation 
Mean 
Difference 
(95%CI) 
P 
value 
Age 
Abnormal 23 56.3 16.7 
10.5 
(3.8-17.2) 
0.002 
 
Normal 1128 45.8 16.3 
Pack years 
Abnormal 7 8.4 8.6 
-1.2 
(-11.8-9.5) 
0.831 
 
Normal 143 9.6 14.1 
Height 
Abnormal 23 156.1 8.9 
-1.3 
(-5.1-2.6) 
0.518 
 
Normal 1128 157.4 9.4 
Weight 
Abnormal 23 60.1 13.6 
-1.2 
(-7.0-4.7) 
0.693 
 
Normal 1128 61.30 14.1 
DM 
duration 
Abnormal 7 99.7 97.9 
35.7 
(-54.8-126.3) 
0.375 
Normal 134 64.0 61.4 
HTN 
duration 
Abnormal 7 71.3 76.4 
12.2 
(-33.3-57.6) 
0.598 
Normal 161 59.1 58.9 
 
People with an abnormal ABI were found to have a significantly higher mean age than 
people with normal ABI. 
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Table 5.32 COMPARISON OF MEANS WITH PAD PATIENTS (Part II) 
 
LDL has been found to be significantly lesser in patients with abnormal ABI. Similar 
findings have not been seen in any previous study. 
  
Exposure ABI N Mean SD 
Mean 
Difference 
(95% CI) 
P 
Value 
Creatinine 
Abnormal 23 1.0 0.2 
0.0 
(-0.1-0.1) 
0.916 
Normal 23 1.0 0.2 
HbA1c 
Abnormal 23 6.5 1.4 
-0.2 
(-1.0-0.7) 
0.661 
Normal 23 6.7 1.5 
Total 
Cholesterol 
Abnormal 23 159.0 22.9 
-23.2 
(-46.9-0.4) 
0.054 
Normal 23 182.2 50.6 
Triglycerides 
Abnormal 23 149.9 80.4 
-51.0 
(-111.1-9.2) 
0.095 
Normal 23 200.9 118.4 
HDL 
Abnormal 23 49.7 9.5 
0.4 
(-5.2-6.2) 
0.866 
Normal 23 49.3 9.6 
LDL 
Abnormal 23 97.5 29.5 
-19.9 
(-39.0- -0.7) 
0.043 
Normal 23 117.4 34.8 
Haemoglobin 
Abnormal 23 12.7 2.8 
0.0 
(-1.5-1.5) 
0.958 
Normal 23 12.7 2.2 
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Table 5.33 LOGISTIC REGRESSION ANALYSIS FOR PAD 
Variable 
Abnormal 
ABI 
Normal ABI 
Unadjusted 
OR (95%CI) 
P value 
Adjusted OR 
(95% CI) 
P 
value 
Sex 
Male 16 (3.7%) 429 (96.3%) 
3.72 
(1.52-9.13) 
0.002 
3.28 
(1.20-8.97) 
0.021 
Female 7 (1.0%) 699 (99.0%) 
Diabetes 
Yes 7 (5.2%) 134 (94.8%) 
3.25 
(1.31-8.03) 
0.007 
2.23 
(0.77-6.42) 
0.138 
No 16 (1.6%) 994 (98.4%) 
Hypertension 
Yes 7 (4.3%) 161 (95.7%) 
2.63 
(1.06-6.49) 
0.03 
1.14 
(0.38-3.37) 
0.818 
No 16 (1.7%) 967 (98.3%) 
Smoking 
Yes 7 (4.9%) 143 (95.1%) 
3.01 
(1.22-7.45) 
0.012 
1.27 
(0.45-3.54) 
0.651 
No 16 (1.6%) 985 (98.4%) 
Age 
≥60 13 (4.6%) 267 (95.4%) 
4.19 
(1.82-9.67) 
<0.001 
3.11 
(1.25-7.72) 
0.015 
<60 10 (1.1%) 861 (98.9%) 
 
Multiple logistic regression analysis was carried out for all variables which were 
significant in the bivariate analysis. Age and Sex continued to be strongly associated 
with abnormal ABI, however Diabetes, Smoking and Hypertension were no longer 
found to be significantly associated with abnormal ABI values. 
  
 78 
 
Table 5.34 Chronic Venous Disorder (CVD) by Age group  
Age 
Chronic Venous Disorder 
Total 
Yes No 
<30 
Frequency 11 207 218 
% 5.0% 95.0% 100.0% 
30-39 
Frequency 11 209 220 
% 5.0% 95.0% 100.0% 
40-49 
Frequency 14 212 226 
% 6.2% 93.8% 100.0% 
50-59 
Frequency 22 185 207 
% 10.6% 89.4% 100.0% 
60-69 
Frequency 19 156 175 
% 10.9% 89.1% 100.0% 
70-79 
Frequency 5 75 80 
% 6.3% 93.8% 100.0% 
≥80 
Frequency 1 24 25 
% 4.0% 96.0% 100.0% 
Total 
Frequency 83 1068 1151 
% 7.2% 92.8% 100.0% 
There is an equal distribution of people with Venous Disorders in each group. 
SES analysis: 
Association between CVD and SES was assessed. The Middle SES group was used as 
the reference and odds ratio was calculated. 
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Table 5.35 Chronic Venous Disorder by SES 
SES 
CVD OR  
(95% CI) 
P 
Value Yes No 
Lower 
Frequency 15 209 0.89  
(0.45-1.76) 
0.739 
% 6.7% 93.3% 
Lower 
Middle 
Frequency 27 371 0.90 
(0.50-1.62) 
0.732 
% 6.8% 93.2% 
Middle 
Frequency 22 273 
1.00 1.000 
% 7.5% 92.5% 
Upper 
Middle 
Frequency 11 146 0.93  
(0.44-1.98) 
0.861 
% 7.0% 93.0% 
Upper 
Frequency 8 69 1.44  
(0.61-3.37) 
0.402 
% 10.4% 89.6% 
Total 
Frequency 83 1068 
  
% 7.2% 92.8% 
 
The middle SES group was taken as the reference point and the association was 
analysed. There was no association found between the different SES groups. 
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Table 5.36 Chronic Venous Disorder by Nutritional Status 
Nutritional Status 
ABI 
OR 
(95% CI) 
P value 
Abnormal Normal 
Underweight 
Frequency 3 116 
0.40 
 (0.12-1.37) 
0.130 
% 2.5% 97.5% 
Normal 
Frequency 20 308 
1.00 1.000 
% 6.1% 93.9% 
Overweight 
Frequency 11 182 
0.93 
 (0.44-1.99) 
0.853 
% 5.7% 94.3% 
Obese 
Frequency 49 462 
1.63  
(0.95-2.80) 
0.075 
% 9.6% 90.4% 
Total 
Frequency 83 1068 
  
% 7.2% 92.8% 
 
Obese individuals were found to be at a higher risk of developing chronic venous 
disease. However, the association was not statistically significant. 
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Table 5.37 BIVARIATE ANALYSIS FOR CHRONIC VENOUS DISORDER 
Factors CVD No CVD 
Odds Ratio 
(95% CI) 
P Value 
Sex 
Male 40 (9.0%) 405 (91.0%) 1.52 
(0.97-2.38) 
0.064 
Female 43 (6.1%) 663 (93.9%) 
Age 
≥60 25 (8.9%) 255 (91.1%) 1.37 
(0.84-2.24) 
0.202 
<60 58 (6.7%) 813 (93.3%) 
Parity 
0 And 1 1 (0.7%) 150 (99.3%) 0.08 
(0.01-0.60) 
0.002 
>1 42 (7.6%) 513 (92.4%) 
Smoking 
Ever 14 (9.3%) 136 (90.7%) 1.39 
(0.76-2.54) 
0.281 
Never 69 (6.9%) 932 (93.1%) 
Diabetes 
Yes 13 (9.2%) 128 (90.8%) 1.36 
(0.73-2.54) 
0.325 
No 70 (6.9%) 940 (93.1%) 
Hypertension 
Yes 16 (9.5%) 152 (90.5%) 1.44 
(0.81-2.55) 
0.210 
No 6.8 (67%) 916 (93.2%) 
Frequency of Fruit Intake 
Less Than Daily 53 (6.0%) 837 (94.0%) 0.49 
(0.30-0.78) 
0.002 
Daily 30 (11.5%) 231 (88.5%) 
CAD 
Yes 1 (6.7%) 14 (93.3%) 0.92 
(0.12 – 7.07) 
0.935 
No 82 (7.2%) 1054 (92.8%) 
Frequency of Vegetable Intake 
Less Than Daily 6 (9.1%) 60 (90.9%) 1.31 
(0.55-3.13) 
0.543 
Daily 77 (7.1%) 1008 (92.9%) 
Alcohol 
Ever 23 (9.4%) 222 (90.6%) 1.46 
(0.88-2.42) 
0.138 
Never 60 (6.6%) 846 (93.4%) 
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Table 5.38 COMPARISON OF MEANS WITH CVD PATIENTS 
 CVD N 
Mean 
(Std. dev) 
MEAN 
DIFFERENCE 
(95% CI) 
P 
VALUE 
ABI 
Yes 83 
1.09 
(0.10) 0.03 
(0.00-0.05) 
0.036 
No 1068 
1.07 
(0.12) 
Height 
Yes 83 
159.8 
(9.3) 2.6 
(0.5-4.7) 
0.016 
No 1068 
157.2 
(9.3) 
Weight 
Yes 83 
66.9 
(14.3) 6.0 
(2.9-9.2) 
<0.001 
No 1068 
60.9 
(14.0) 
BMI 
Yes 83 
26.20 
(5.13) 1.60 
(0.44-2.76) 
0.007 
No 1068 
24.60 
(5.19) 
Pack Years 
Yes 14 8.6 (8.7) 
-1.0 
(-8.8-6.6) 
0.788 
No 136 9.6 (14.3) 
Smoking Duration 
Yes 14 
13.4 
(10.8) -3.1 
(-10.8-4.7) 
0.438 
No 136 
16.5 
(14.1) 
Diabetes Duration 
Yes 13 
71.5 
(57.4) 6.3 
(-30.4-43.1) 
0.733 
No 128 
65.2 
(64.5) 
Hypertension 
Duration 
Yes 16 
46.7 
(46.2) -14.3 
(-45.2-16.6) 
0.362 
No 152 
61.0 
(60.7) 
Age 
Yes 83 
49.4 
(15.0) 3.6 
(-0.002-7.303) 
0.050 
No 1068 
45.8 
(16.4) 
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Comparison of means revealed that the mean ABI was significantly higher among 
patients with CVD. Patients with CVD were also found to be 2 cm taller on an 
average. However, the strongest association was found between weight and CVD. A 
patient with CVD averaged 6 kg more than a normal person. 
Table 5.39 LOGISTIC REGRESSION ANALYSIS FOR CVD 
Factors CVD No CVD 
Unadjusted 
OR 
(95% CI) 
P 
value 
Adjusted OR 
(95% CI) 
P 
value 
Parity 
0 and 1 
1 
(0.7%) 
150 
(99.3%) 0.08 
(0.01-0.60) 
0.002 
0.07 
(0.01-0.53) 
0.010 
>1 
42 
(7.6%) 
513 
(92.4%) 
Frequency of Fruit Intake 
Less Than 
Daily 
53 
(6.0%) 
837 
(94.0%) 0.49 
(0.30-0.78) 
0.002 
0.26 
(0.14-0.49) 
<0.001 
Daily 
30 
(11.5%) 
231 
(88.5%) 
 
Multiple Logistic Regression analysis was done which reiterated earlier findings. 
Increased frequency of fruit intake and multiparity were found to be significant risk 
factors. 
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6. DISCUSSION 
The majority of the study population were women, followed Hinduism and literate. 
We can decipher that 36.9% have studied till primary school and unsurprisingly 
27.2% are illiterate with 6.1% people knowing how to read alone. This amounts to 
only two-thirds of the study participants knowing how to read and write which is 
consistent with the rural literacy rate in Tamil Nadu of 73.54% (158). 
33.7% of the men had ever smoked and 55.1% of the men had ever consumed alcohol. 
This was a less than the prevalence of current smoking (37.6%) and alcohol 
consumption (62.4%) estimated among men in a study done in a rural area in 
Kanchipuram district of Tamil Nadu (159). 
The mean height of the study population was approximately 157 cm and the mean 
weight was 61 kg. The Mean BMI of the participants was 24.72 kg/m². This is very 
similar to findings in another study done in another rural area in Villupuram, Tamil 
Nadu which showed a mean BMI of 24.5 kg/m² (160). 
The prevalence of overweight individuals in this study is similar to study findings 
done in Tamil Nadu in 2015 (161) which showed a prevalence of 15.2% of people 
with a BMI between 23.00-24.99 kg/m². Another study estimated a prevalence of 
39.64% people with a BMI above 25 in rural Tamil Nadu (162) which is similar to our 
study numbers (44.4%). 
14.6% of our study population were on medications for hypertension. A study done in 
rural Tamil Nadu showed a prevalence of 21.4% (163). 
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The proportion of people on medications for diabetes mellitus in our study population 
was 12.3%. This is similar to the estimated prevalence of 10.4% in another large-scale 
cross-sectional study (164) 
15 people (1.3%) have had pre-existing Coronary Artery Disease (CAD). A study on 
the prevalence of CHD among a similar population showed the prevalence of pre-
existing CAD as 0.6% (165). 
1% of the total study population had suffered a stroke in their lifetime. In another 
study done in a rural area of Tamil Nadu, the prevalence of CVA confirmed by 
CT/MRI findings was 1.3 per 1000 population (166).  
Prevalence of intermittent claudication in the study population was 3.8%. A previous 
study was done in rural Vellore using the Rose questionnaire which estimated a 
prevalence of classical claudication at 3.8% (167). 
Chronic Venous Disorder (CVD) was seen in 7.2% (95%CI 5.7%-8.8%) of the 
study population. As has already been mentioned, it has been extrapolated that 15%-
20% of our population have Chronic Venous Disorders (19). 
The Prevalence of Abnormal ABI in the study population has been estimated at 
2% (95% CI 1.3%-3%). Other studies have shown the prevalence of PAD to be 
between 3 % to 7%. (155, 157). 
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Arterial Disease: 
As previously discussed, the NHANES study(41) has shown the following prevalence 
of PAD in each age group, 
Table 6.1 NHANES study vs Present Study with regards to age distribution 
Age Group NHANES study(41) Present Study 
> 80 years 23.2% 4.0% 
> 70 years 14.5% 6.1% 
60 - 69 years 4.7% 4.0% 
50 - 59 years 2.5% 1.9% 
40 - 49 years 0.9% 0.4% 
30-39 years N/A 0.9% 
<30 years N/A 1.4% 
 
Increasing age has thus been found to be a significant risk factor for peripheral arterial 
disease in this study with an adjusted Odds Ratio of 3.11 ( 1.25-7.72). 
In this study, the prevalence of PAD in men above 18 years of age was 3.7% and 
among women in the same age group was 1.0%. Though in dissimilar populations 
(age >65) it is similar to findings in others studies that have been mentioned 
above(54). 
In bivariate analysis, a history of Diabetes Mellitus was found to be significantly 
associated with PAD (OR 3.25, 95%CI 1.31-8.03). However, while accounting for 
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age, sex, smoking and hypertension in logistic regression, the association was found to 
be not significant (adj OR 2.23, 95% CI 0.77-6.42). 
 
Similarly, hypertension was found to be significantly associated with PAD (OR2.63, 
95%CI 1.06-6.49) in bivariate analysis but was not significant in logistic regression 
(adj OR 1.14, 95% CI 0.38-3.37). 
Another variable which was a significant risk factor in bivariate analysis but not 
significant after regression analysis was smoking (OR 3.01[1.22-7.45] vs adj OR 
1.27[0.45-3.54]). 
This shows that age and sex were the predominant risk factors and acted as 
confounders during bivariate analysis. 
The mean age in the abnormal ABI group was significantly higher (10.5, 95% CI 3.8-
17.2) than in the normal ABI group. 
LDL has been found to be significantly lesser in patients with abnormal ABI (-19.9, 
95% CI -39.0 to -0.7). Similar findings have not been reported in any previous study. 
There were no significant differences in any of the other blood investigations. 
 
Venous Disease: 
Multigravida women were found to be at a higher risk of developing chronic venous 
disorders than nulliparous women and women who have had only one delivery in the 
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past. Women with lesser parity were 92% (OR 0.08, 95%CI 0.01-0.60) less likely to 
develop venous disease as opposed to women with parity >1. 
Though the association between obesity and chronic venous disease was not 
significant, the mean BMI was significantly higher in the CVD group (Mean 
Difference 1.60 kg/m², 95% CI 0.44-2.76).  
The CVD group were also significantly taller (Mean Difference 2.6 cm, 95%CI 0.5-
4.7) and remarkably heavier (Mean Difference 6.0kg, 95% CI 2.9-9.2) than their 
counterparts. 
The Ankle Brachial Index (ABI) was also found to be minimally but significantly 
higher (0.03, 95%CI 0.00-0.05) in the CVD group. 
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7. LIMITATIONS 
Toe-Brachial Index (TBI) would have been the ideal tool to diagnose PAD. This is 
because ABI values >1.30 must be confirmed by TBI for diagnosis of PAD.  
However, due to practical constraints it could not be done. 
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8. CONCLUSIONS 
• The prevalence of Peripheral Arterial Disease in Kaniyambadi block was 2% 
(95% CI: 1.3%-3%). 
 
• The prevalence of Chronic Venous disorders in Kaniyambadi block was found 
to be 7.2% (95% CI: 5.7%-8.8%). 
 
 
• Peripheral Arterial disease was significantly associated with increased age  
(>60 years) and male gender. 
 
• Chronic Venous Disorders were significantly associated with increased parity. 
 
 
• The mean height, weight and BMI were all significantly higher among people 
with Chronic Venous Disorders. 
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9. RECOMMENDATIONS 
• Routine Ankle Brachial Index should be done in men above the age of 60 years 
to screen for Peripheral Arterial Disease. 
 
• Ankle Brachial Index may also be useful to screen for Peripheral Arterial 
Disease among diabetics and hypertensives. 
 
 
• Lifestyle modification in the community may be essential to bring down the 
high proportion of obese people. 
 
• A dwindle in number of people with overweight and obesity may decrease the 
prevalence of chronic venous disorders. 
 
 
• Early screening and intervention at the community level may help in avoiding 
the natural progress of both PAD and CVD thereby improving quality of life 
and reducing morbidity and mortality. 
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Annexure 1 - Questionnaire                           
      Date 
1. S.No: 
2. Household No: 
3. Subject Id: 
4. Name : 
5. Village :     Street:    Door No: 
6. Age: 
7. Sex:   Male  Female  Transgender 
8. Religion:  Hindu  Muslim   Christian  Others   
9. Caste (specify): 
10. Education: Nil Primary school  Middle school  
 High school  
Higher Secondary/Diploma Graduate/Post Graduate Professional/Honours 
 
11. Literacy:  Illiterate Read  Read & write  
12. Occupation:_______________________________  
 Unemployed   /   Unskilled   /   Semi-skilled   /   Skilled   /   Clerical, 
shop owner, farmer   /   Semi-professional   /   Professional 
 
13. How often do you eat fruits:  daily/........ a week/.........a month/less than 
monthly 
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14. How often do you eat vegetables: daily    /   ........ a week    /    ......... a month    
/    less than monthly 
15. Type of family:   Nuclear  / Extended or Joint   
16. Number of members in the family: _______ 
17. Family income /month (total)   ________ 
18. BG Prasad scale-social class  _________  
19. CHAD/CMC Hospital number: 
20. Are you a diabetic? Yes / No 
21. If yes, how long have you had diabetes?   _______ Yrs _______Mths 
22. What type of Medications are you on for Diabetes? 
23. Is there documented evidence of Diabetic Retinopathy:  Yes    /    No  
 
24. Are you a hypertensive?  Yes / No  
25. If yes, how long have you had hypertension?  _______ Yrs _______Mths 
26. What medications are you on for Hypertension? 
 
27. Have you ever smoked?  Yes-Current   /    Yes-Past   /   Never (If 
Never, go to Q.33) 
28. (If ‘Yes to 27) – Do/Did you smoke Daily?  Yes/No      (if No, go 
to Q.33) 
29. How many cigarettes do/did you smoke per day?_____ 
30. How many beedis do/did you smoke per day?_____ 
31. How long have you been smoking?_ _ _ _ _ _ _ _ (yrs) 
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32. Pack Years of smoking _ _ _ _ _ _ _ _ 
33. In the last 7 days, on how many days were you exposed to a person who was 
smoking in your home/workplace_______(range 0-7)? 
34. Have you ever consumed alcohol? Yes-Current   /    Yes-Past   /   Never  (If 
Never, go to Q.37 or 40) 
35. If yes, how often do/did you consume alcohol?  
daily    /  ........ a week    /    ......... a month    /     less than monthly 
36. On an average (usually) how much alcohol (hard liquor/beer/wine/local drinks) 
do you consume on the days that you drink?_ _ _ __ _ml of _ _ _ _ _ _ _ _ _ _ 
_  
_ _ _ __ _ml of _ _ _ _ _ _ _ _ _ _ _ 
_ _ _ __ _ml of _ _ _ _ _ _ _ _ _ _ _ 
37. (For females only)Parity: 
38. (For females only)Have you taken OCPs?    Yes   /   No 
39. (If yes to Q38)Total duration: _ _ _ _ _ _ _Yrs _ _ _ _ _ _ _ _Months 
 
40. Past history of Stroke/TIA: Yes / No  
41. Past history of coronary artery disease:  Yes / No  
The Edinburgh Claudication questionnaire: 
42.  Do you get pain or discomfort in your leg(s) when you walk?  Yes   /    
No   /    Unable to walk (if no, proceed to Q. No  48) 
43. If yes, does this pain ever begin when you are standing still or sitting? 
 Yes    /    No  
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44. Do you get pain if you walk uphill or hurry?  Yes    /    No   
45. Do you get it when you walk at an ordinary pace on level ground?  Yes    /    
No  
46. What happens to it when you stand still?  Continues > 10 mins     /     
Disappears in <10 mins  
47. How long do you walk before you get the pain/discomfort in your legs? 
_______ m 
48. Height (cm)_ _ _ _ _ _ _ _ _ 
49. Weight (kg) _ _ _ _ _ _ 
50. Left upper limb peripheral pulse:  Present    /     Absent 
51. Right lower limb peripheral pulse:            Present    /     Absent  
52. Left  lower limb peripheral pulse:  Present    /     Absent  
53. (Local exam) : Gangrene  Yes  /   No 
54. (Local exam) CEAP classification:  Telangiectasia  /  Varicose veins  /   Ankle 
Oedema  /   Lipodermatosclerosis  /   Healed Ulcer  /  Active Ulcer   
55. Left Upper limb Systolic Blood pressure:_______ 
56. Right Lower Systolic limb Blood Pressure:  _______ 
57. Left lower limb Systolic blood pressure:______ 
58. ABPI : 
59. Peripheral Vascular Disease:  Yes / No 
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For Selected Cases and Controls 
60. Category: Case  / Control 
61. Value of Creatinine:   (Date of last creatinine:    ) 
62. HbA1C value:    (Date of last HbA1C :  ) 
63. Lipid Profile Value:   (Date of last Lipid profile :  ) 
64. Haemoglobin: 
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Annexure 2 – Information Sheet and Consent Form – English 
 
Information sheet 
Name of the principle investigator: Jackwin Sam Paul G., CHAD, Bagayam, Vellore – 
632002. Phone no : 94431 51015. E-mail id : jackwinsp@gmail.com 
Name of the organization: Department of community health, Christian Medical College, 
Vellore 
Title: Prevalence of Peripheral Vascular Disease in the Community and associated risk 
factors: a cross sectional study 
We are doing a study to find out the prevalence of peripheral vascular disease among the 
general population and its causes in kaniyambadi block. We are inviting you to participate in 
the study. Please review this form carefully and ask any questions about the study before you 
agree to join. You may also ask questions at any time after joining the study 
Purpose:  
Diabetics are at an increased risk for peripheral occlusive arterial disease. Peripheral arterial 
disease has a huge economic burden on the family and the community there are no existing 
data regarding prevalence of peripheral vascular disease in a rural community. This study 
aims to fill the knowledge gap and find out the prevalence of peripheral vascular disease 
among diabetics in Kaniyambadi block.  
.  
Procedure: You are invited to participate in the study. A questionnaire will be administered 
to you. Your blood pressure will be measured, both upper and lower limbs, using a Doppler 
machine and a ratio is taken to determine disease (Ankle Brachial Ppressure Index).A blood 
test will be taken from you. Not more than 6 mL will be drawn from you. 
Side effects: There may be bleeding or infection at the site of drawing blood. 
Risks and discomfort: There will not be any or discomfortto you as the procedure is non-
invasive. Blood sample will be taken in CMC to check for your  haemoglobin, white blood 
cell counts, platelet counts, fasting and post prandial blood glucose levels, serum creatinine 
values as well as lipid (cholesterol) levels. 
Benefits: Your participation is likely to help us find answers about peripheral vascular 
disease among diabetics in Kaniyambadi block. 
Expenses: All investigations will be done free of cost for the patient. No cash incentives will 
be given for taking part in the study.  
Confidentiality: The information that we collect from this research project will be kept 
confidential. Information about you that will be collected from the study will be stored in a 
file and will be kept locked with access only to the primary investigator.  
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Right to refuse or withdraw: You do not have to join in this research if you do not wish to 
do so. You may stop participation in the research at any time without losing any of your 
rights as a patient here. Your treatment at this center will not be affected in any way. 
If new information becomes available: Sometimes, after a research study has started, the 
researchers learn new things about peripheral vascular disease or ankle brachial pressure 
index. If this happens, we will tell you about the new information. Then you can decide 
whether you will continue participating. 
Whom to contact: If you have any questions you may ask them now or later. If you wish to 
ask questions later, you may contact the principal investigator in CHAD, Bagayam, Vellore. 
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Informed Consent form to participate in a research study  
 
Study Title: Incidence of Diabetic Neuropathy among diabetics  
and associated risk factors: a concurrent cohort study 
Study Number: ____________Subject’s  Initials:___________  
Subject’sName: _________________________________________ 
Date of Birth / Age: ___________________________ 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ 
for the above study and have had the opportunity to ask questions. [  ] 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [  ] 
(iii)  I understand that the Ethics Committee and the regulatory authorities will not need 
my permission to look at my health records both in respect of the current study and 
any further research that may be conducted in relation to it, even if I withdraw from 
the trial. I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [  ] 
(v)  I agree to take part in the above study. [  ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
Or 
 
Representative: _________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signat.ure of the Investigator: ________________________ 
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Date: _____/_____/______ 
Study Investigator’s Name: ________________________ 
Signature or thumb impression of the Witness: ___________________________ 
Date: _____/_____/_______Name & Address of the Witness: 
_____________________________ 
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Annexure 3 – Information Sheet and Consent Form – Tamil 
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Annexure 4 – Institutional Review Board Approval letter 
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